Document:

Form of Environmental Matters Agreement

 Exhibit 10.13 
 FORM OF ENVIRONMENTAL MATTERS AGREEMENT 
 This ENVIRONMENTAL MATTERS
AGREEMENT, dated as of [—], 201[—], is by and among PFIZER INC., a Delaware corporation and ZOETIS INC., a Delaware corporation. 

R E C I T A L S 
 WHEREAS, the Board of Directors of Pfizer Inc. has determined that it is in the best interests of Pfizer Inc. and its stockholders to separate the Animal Health Business from the other businesses
conducted by Pfizer Inc. and its Subsidiaries; 
 WHEREAS, pursuant to the Contribution Agreement (as defined below), Pfizer
Inc. and Zoetis Inc. have undertaken the transfer of certain of the Animal Health Assets, including the stock or other equity interests of certain of Pfizer Inc.’s Subsidiaries owning Animal Health Assets and/or dedicated to the Animal Health
Business, by Pfizer Inc. to Zoetis Inc. and the assumption of the Animal Health Liabilities by Zoetis Inc.; 
 WHEREAS, pursuant
to the Separation Agreement (as defined below), Zoetis Inc. assumed certain Environmental Liabilities, as described in Section 2.04 of the Separation Agreement; 
 WHEREAS, Pfizer Inc. and Zoetis Inc. are entering into this agreement (this “Environmental Matters Agreement”) because they mutually agree that it is in the best interest of the Pfizer
Group (all members of which shall be referred to herein as “Pfizer”) and the Company Group (all members of which shall be referred to herein as the “Company”) to drive Remedial Actions to closure in the most
efficient manner and in order to address the exchange of certain information between the parties, the Company’s performance of Remedial Actions pursuant to Liabilities it was allocated under the Separation Agreement, the use of consultants and
contractors to assist in the conduct of Remedial Actions, and certain conduct at Co-Located Facilities, including each of Pfizer’s and the Company’s rights to access such sites, the use of institutional controls, notification procedures,
procedures for communicating with Governmental Authorities, responsibilities for releases of hazardous materials, construction and redevelopment activities, liability protection, and procedures in the event of a dispute between the parties, and to
assure that the Company complies with all requirements of Environmental Laws pending its substitution for Pfizer, both at its operating facilities and in connection with its conduct of Remedial Actions, and that the Company obtains the consent of
Governmental Authorities, to the maximum extent achievable, to replace Pfizer as the permittee or legally responsible party in each case, after the Effective Date; and 
 WHEREAS, Pfizer Inc. and Zoetis Inc. are entering into this Environmental Matters Agreement in order to also address certain conduct related to each of Pfizer’s and the Company’s operations or
conduct of Remedial Actions at Co-Located Facilities, including facilities located in Catania, Italy; Guarulhos, Brazil; Kalamazoo, Michigan; and Hsinchu, Taiwan. 

 NOW, THEREFORE, in consideration of the mutual agreements, provisions and covenants
contained in this Environmental Matters Agreement, the parties, intending to be legally bound, hereby agree as follows: 

ARTICLE I 

DEFINITIONS 
 Section 1.01. Certain Definitions. For the purpose of this Environmental Matters Agreement, the following terms shall have the meanings indicated. Capitalized terms used herein and not otherwise
defined shall have the respective meanings set forth in the Separation Agreement. 
 “Catania Remediation
Matter” shall have the meaning as set forth in Section 7.02 of this Environmental Matters Agreement. 

“Catania Remediation Matter Reports” shall mean the Environmental Site Characterization Report according to DM471/99:
Wyeth Catania Site dated January 31, 2005 and prepared by ERM Italia S.p.A. in Milan; Integrative Investigation Characterization Report according to D. Lgs. 152/06: Wyeth Catania Site dated May 15, 2009 and prepared by ERM
Italia S.p.A. in Milan; and Site Specific Risk Assessment According to Legislative Decree 152/06: Catania Facility dated May 25, 2009 and prepared by ERM Italia S.p.A. in Milan. 

“Co-Located Facilities” shall mean the real property listed on Schedule 1.01 to this Environmental Matters Agreement.

 “Company’s Catania Facility” shall have the meaning as set forth in Section 7.01 of this
Environmental Matters Agreement. 
 “Company’s South Campus Kalamazoo Facility” shall have the meaning as
set forth in Section 8.01 of this Environmental Matters Agreement. 
 “Contribution Agreement” shall have
the meaning set forth in the Separation Agreement. 
 “Environmental Permit Transfer Agreements” shall mean
those agreements executed to effectuate the transfer of environmental permits and the responsibility, coverage, and Liability thereunder from Pfizer to the Company. 
 “Governmental No Further Action Letter” shall mean written notice from the appropriate Governmental Authority that, with respect to contamination or an actual or threatened Release of
Hazardous Material no further Remedial Actions are required. 
 “Guarulhos Leased Facility” shall have the
meaning set forth in Section 9.01 of this Environmental Matters Agreement. 

  
 2 

 “Guarulhos Remediation Matter” shall have the meaning as set forth in
Section 9.01 of this Environmental Matters Agreement. 
 “Guarulhos Remediation Matter Reports” shall mean
[                                ]. 

“Institutional Controls” shall have the meaning as set forth in Section 4.02 of this Environmental Matters
Agreement. 
 “Kalamazoo Environmental Matter” shall have the meaning as set forth in Section 8.01 of this
Environmental Matters Agreement. 
 “Kalamazoo Environmental Matter Report” shall mean Pharmacia & Upjohn,
LLC Hazardous Waste Management Facility Operating License Annual Groundwater Report. 
 “Lease Term” shall mean
the period in which Pfizer is leasing a referenced property from the Company pursuant to a lease agreement. 

“Pfizer’s Kalamazoo Facility” shall have the meaning as set forth in Section 8.01 of this Environmental
Matters Agreement. 
 “Remedial Action” shall mean all actions required by Environmental Law or by a
Governmental Authority pursuant to Environmental Law or required pursuant to an order, writ, judgment, injunction, decree, stipulation, determination or award entered by, into, or with any Governmental Authority pursuant to Environmental Law to
(i) cleanup, remove, treat, investigate, monitor, assess, evaluate, contain, or remediate Hazardous Materials in the indoor or outdoor environment; (ii) prevent the Release of Hazardous Materials so that they do not migrate, endanger, or
threaten to endanger public health or welfare or the indoor or outdoor environment; (iii) perform pre-remedial studies and investigations and post-remedial monitoring and care; (iv) respond to any governmental requests for information or
documents regarding any Hazardous Materials; (v) prepare reports, studies, analyses, or other documents regarding any Release or threatened Release of Hazardous Materials; or (vi) otherwise address or respond to a Release or threatened
Release of Hazardous Materials, including, for example, through the use of Institutional Controls. “Remedial Action” also shall mean any judicial, administrative or other proceedings relating to any of the above and all actions
associated therewith, including the negotiation and execution of judicial or administrative consent decrees and the defense of claims brought by any Governmental Authority or any other Person, whether such claims are equitable or legal in nature,
relating to any of the above. For avoidance of doubt, “Remedial Action” shall not include (a) the capital, operational, or maintenance costs incurred by the Company to continue to operate an Animal Health Asset after the
Effective Date; or (b) facility closure or post-closure expenditures related to an Animal Health Asset or a portion thereof. 
 “Remedial Action Outcome” shall mean (i) a Governmental No Further Action Letter or (ii) if a Governmental No Further Action Letter is not available, or self-implementation or

  
 3 

 
notice-only mechanisms for Remedial Action are available, under the regulatory regime under which the Remedial Action is being conducted, a good faith determination from the party’s
environmental consultant that no further investigation or remediation is required to meet applicable Remediation Standards and that the Remedial Action has adequately addressed any threats to human health and the environment. 

“Remediation Standard” shall mean a standard that defines the concentrations or conditions of Hazardous Materials that
may be permitted to remain in any environmental media after a Release of Hazardous Materials. 
 “Separation
Agreement” shall mean the Global Separation Agreement, as amended from time to time, by and between Pfizer Inc. and Zoetis Inc. 
 ARTICLE II 
 EXCHANGE OF INFORMATION 

Section 2.01. Exchange of Information. Consistent with Article VI of the Separation Agreement, each of Pfizer Inc. and Zoetis
Inc., on behalf of its respective Group, agrees to provide, or cause to be provided, at any time before, on, or after the Effective Date, as soon as reasonably practicable after written request therefore, reasonable access to any non-privileged
Information in the possession or under the control of such respective Group and reasonable access to its employees to the extent that (i) such Information relates to, or such employees have relevant knowledge regarding, the requesting
party’s alleged or potential link to environmental contamination at a third-party location; and (ii) the Information and access to employees can be provided without disruption to the Group’s business or operations. 

ARTICLE III 
 SUBSTITUTION OF THE COMPANY FOR PFIZER WITH RESPECT TO REMEDIAL ACTIONS AND ON-GOING OPERATIONAL MATTERS AND ALLOCATION OF LIABILITIES 

Section 3.01. Substitution. Pursuant to Sections 2.01 and 9.01 of the Separation Agreement, the Company shall use its best efforts
to obtain and assist Pfizer to obtain any consents, transfers, assignments, assumptions, waivers, or other legal instruments necessary to cause the Company to be fully substituted for Pfizer with respect to: (i) any Remedial Actions associated
with Liabilities allocated to the Company pursuant to the Separation Agreement or this Environmental Matters Agreement or (ii) any Animal Health Asset. This substitution shall include substituting the Company for Pfizer with respect to consent
decrees, consent orders, other decrees or orders, permits, licenses, registrations, approvals, financial assurances (including letters of credit), Actions, and voluntary cleanup agreements. The Company shall

  
 4 

 
inform the applicable Governmental Authorities about its assumption of the Liabilities described on Schedule 3.01 and request that the Governmental Authorities direct all communications,
requirements, notifications and/or official letters related to such matters to the Company. The Company’s assumption of Liabilities pursuant this Environmental Matters Agreement shall comply with Section 2.01 of the Separation Agreement.

 Section 3.02 Compliance Pending Substitution. Until such time as the Company and Pfizer complete the substitutions
outlined in Section 3.01 above or until the Effective Date, whichever is later, the Company shall: (i) comply with all Environmental Laws, including all reporting obligations, and the terms and conditions of all decrees, orders, permits,
licenses, registrations, approvals, financial assurances and agreements that remain in Pfizer’s name and (ii) provide Pfizer (A) annual progress reports on any such Remedial Action, other than those occurring at Co-Located Facilities
where such information sharing obligations are governed by Articles VI through X of this Environmental Matters Agreement, including a summary of actions taken during the past year and of actions expected to be taken in the future; and (B) prior
written notice that the Company intends to change or hire additional environmental consultants or contractors to perform work on any part of such Remedial Action. 
 ARTICLE IV 
 PERFORMANCE OF REMEDIAL ACTIONS 

Section 4.01. Responsibility for Remedial Actions. 
 (a) The Company shall be responsible for the performance of and payment of costs related to Remedial Actions associated with Liabilities allocated to the Company pursuant to the Separation Agreement or
this Environmental Matters Agreement and required under Environmental Laws at: (i) certain Co-Located Facilities, subject to the provisions of this Environmental Matters Agreement; (ii) real property that is an Animal Health Asset that the
Company will own after the Effective Date and that will not be a Co-Located Facility; (iii) certain real property at which a Remedial Action is related to, arises out of, or results from any of the terminated, divested or discontinued
businesses and operations of Pfizer and its Subsidiaries that would have comprised part of, or related to, the Animal Health Business had they not been terminated, divested or discontinued prior to the Effective Date and (iv) any third-party
disposal location where Hazardous Materials were disposed of that were generated at any real property, or portions thereof, that is or was an Animal Health Asset, regardless of whether such real property is owned by the Company after the Effective
Date or was divested prior to the Effective Date and regardless of when the disposal of Hazardous Materials occurred. 

  
 5 

 (b) Pfizer shall be responsible for the performance of and payment of costs related to
Remedial Actions associated with Liabilities allocated to the Company pursuant to the Separation Agreement or this Environmental Matters Agreement and required under Environmental Law at: (i) certain Co-Located Facilities, subject to the
provisions of this Environmental Matters Agreement; and (ii) a third-party disposal site where Hazardous Materials generated on behalf of the Animal Health business were disposed of (regardless of the date of the disposal), if such Hazardous
Materials were generated at real property, or portions thereof, that will be owned or operated by Pfizer after the Effective Date. 
 Section 4.02 Conduct of Remedial Actions. 
 (a) Pfizer, with respect to any
Remedial Action that it conducts pursuant to Article VI, and the Company, with respect to any Remedial Action that is associated with a Liability allocated to it under this Environmental Matters Agreement and the Separation Agreement, shall:

 (i) diligently conduct and control such Remedial Action in a good, safe, and workmanlike manner, in accordance
with all applicable Laws, including all applicable Environmental Laws, in accordance with all instructions from any applicable Governmental Authority, and with generally accepted industry practices consistent with practices of responsible
multi-national corporations. 
 (ii) complete the Remedial Action in a prompt and expeditious fashion,
provided that Pfizer or the Company, as applicable, may, within reason, exercise its rights, including its due process right, to contest any requirement imposed or determination made by a Governmental Authority with respect to the
contemplated Remedial Action; and 
 (iii) not cause, through any action or inaction, any undue delay in
undertaking any Remedial Action or achieving a Remedial Action Outcome, and shall comply with all Environmental Laws, and protect human health and the environment. 
 (b) It is expressly acknowledged and agreed by the parties that Pfizer and the Company, as applicable, may, if approved or permitted by the applicable Governmental Authority or Environmental Law, use deed
notices, deed restrictions, engineering controls, ordinances, or other institutional controls (all of which are referred to here as “Institutional Controls”) to complete a Remedial Action associated with a Liability allocated to it
under the Separation Agreement. 
 (c) Nothing in this Environmental Matters Agreement shall be construed to obligate Pfizer or
the Company to conduct, or pay for the conduct of, a Remedial Action to meet a 

  
 6 

 
Remediation Standard that is more stringent than the least stringent, most cost effective Remediation Standard or remedy (including, for example, long-term natural attenuation, containment, or
installation and maintenance of a cap) that: (i) is in effect and enforceable under applicable Environmental Law as of the date the Remedial Action Outcome is issued, (ii) is the source of the obligation to conduct the Remedial Action, and
(iii) is consistent with the industrial/commercial use of the site at which the Remedial Action is being conducted as of the day before the Effective Date. 
 Section 4.03. Information Sharing. The Company shall promptly provide Pfizer copies of any Remedial Action Outcome (and any relevant supporting documentation requested by Pfizer) with respect to
any Remedial Action associated with a Liability allocated to it under the Separation Agreement. 
 ARTICLE V 

USE OF CONSULTANTS 
 Section 5.01. Hiring Consultants. If in undertaking a Remedial Action associated with a Liability allocated to it under the Separation Agreement each of the Company or Pfizer chooses to use an
environmental consultant or contractor, the parties each agree to use a competent, and qualified environmental consultant or contractor who has the proper credentials to conduct the tasks for which he or she was retained. 

Section 5.02. Continuity of Consultants. The parties agree that the Company may use, after the Effective Date, the same
environmental consultant(s) or contractor(s) utilized by Pfizer to manage a specific Remedial Action prior to the Effective Date, unless Pfizer communicates an objection to the use of a specific consultant or contractor to the Company’s
remediation lead within ninety (90) days after the Effective Date. Should Pfizer timely object to the use of a specific consultant or contractor, Pfizer shall be responsible for the reasonable costs to transition the matter to a new consultant
or contractor. With respect to those environmental consultants about whom Pfizer does communicate a timely objection, the Company may not retain them for any purpose related to that specific Remedial Action other than effecting a reasonable
transition to a new consultant or contractor. Further, Pfizer may retain such consultant or contractor for any purpose, including to support, evaluate, testify, or otherwise support Pfizer in any claim or dispute with the Company related to the
specific Remedial Action. With respect to an environmental consultant or contractor who is not the subject of a timely objection from Pfizer: (i) the Company may continue to use them to manage any Remedial Action but is barred from using such
consultant or contractor to support, evaluate, testify, or otherwise support the Company in any claim or dispute with Pfizer related to the Remedial Action that is the subject of the claim or dispute, until after the fourth anniversary of the
Effective Date, and (ii) after the fourth anniversary of the Effective Date, Pfizer is barred 

  
 7 

 
from using such consultant or contractor to support, evaluate, testify, or otherwise support Pfizer in any claim or dispute with the Company related to the Remedial Action that is the subject of
the claim or dispute. Pfizer may request information from the consultant or contractor after the fourth anniversary to defend against a claim or dispute, and the Company shall cooperate with such requests consistent with the provisions of
Section 2.01 of this Environmental Matters Agreement. 
 ARTICLE VI 

CO-LOCATED FACILITIES 
 Consistent with the foregoing, the parties agree and acknowledge the following with respect to Co-Located Facilities: 
 Section 6.01. Access. Each of the parties hereby grant to the other party and its Group, employees, agents, representatives, contractors, and consultants a non-exclusive license to reasonably
access and enter onto its portion of any Co-Located Facility and use such infrastructure or utility services at its portion of any Co-Located Facility, from time to time and with seven (7) business days advance notice, as may be reasonably
necessary to conduct any Remedial Action that is necessary in the other party’s reasonable technical judgment or to use such utilities in the other party’s on-going operations pursuant to a Site Services Agreement, including, providing the
other party with reasonable access to employees, documents, and on-site structures (including underground piping, sewer systems, or waste water treatment facilities) (“Access License”). In so doing, the other party shall not
materially impact the operations at the granting party’s portion of the Co-Located Facility and shall pay the granting party reasonable utility costs upon presentation of an itemized invoice by the granting party. The Access License for each
Co-Located Facility shall commence upon the Effective Date and shall terminate, expire, and be revoked when Pfizer or the Company, as applicable, no longer owns, leases, or operates at least a portion of such real property and is no longer
conducting a Remedial Action at such real property. The parties agree that entry upon the granting party’s portion of any Co-Located Facility shall be limited to the extent necessary for the performance of the activities herein described and no
other purpose. When accessing the granting party’s portion of any Co-Located Facility, the other party shall comply at all times with applicable Laws and any environmental, health and safety standards of the granting party. 

Section 6.02. Institutional Controls. It is expressly acknowledged and agreed by the parties that the Company and Pfizer may, if
approved or permitted by the applicable Governmental Authority or Environmental Law, use Institutional Controls to complete a Remedial Action at or related to a Co-Located Facility. Where the use of such Institutional Controls are necessary or
appropriate, the parties agree, on behalf of their respective Groups, to cooperate with the other to seek, execute and record such controls. 

  
 8 

 Section 6.03. Notification. Each of Pfizer and the Company shall promptly notify the
other party of (i) any planned change in its operations at a Co-Located Facility that may reasonably be expected to impact the other party’s permits, employees, property, operations or an on-going Remedial Action conducted by the other
party at the Co-Located Facility; (ii) any Release or threatened Release of Hazardous Materials at, on, under, or from a Co-Located Facility to the extent such Release requires reporting to a Governmental Authority under any applicable
Environmental Law; or (iii) the discovery of any contamination in the soil, groundwater, surface water, or air at, on, under, or from a Co-Located Facility. 
 Section 6.04. Communications with Governmental Authorities. Except in the case of an emergency situation in which there is a substantial risk of loss of life or severe injury to any Person if
reporting is delayed by the following consent process, each of Pfizer and the Company shall not initiate any contact with or initiate any disclosure to any Governmental Authority in relation to any matter at a Co-Located Facility for which the other
party would reasonably be expected to have Liability pursuant to the allocation of Liabilities under the Separation Agreement and this Environmental Matters Agreement without the other party’s prior written consent, which consent shall not be
unreasonably withheld. 
 Section 6.05. Responsibility for Hazardous Material Releases. Pursuant to the allocation of
Liabilities under the Separation Agreement, each of Pfizer and the Company shall be responsible for conducting and paying the costs related to any and all Remedial Actions to address any Release or threatened Release of Hazardous Materials caused by
or attributable to it or its respective operations at a Co-Located Facility that occurs after the Effective Date to meet applicable Remediation Standards, in conformance with the requirements of applicable Governmental Authorities, and to achieve
compliance with Environmental Laws, including reporting such Release or threat of Release to the appropriate Governmental Authorities. 
 Section 6.06. Construction or Redevelopment Activities. Except as otherwise provided elsewhere in this Environmental Matters Agreement, and subject to any contractual limitations, limitations under
Law, and restrictions provided in a Governmental No Further Action Letter, each of Pfizer and the Company is permitted to conduct changes to its operations or any necessary construction or redevelopment activities for a bona fide business purpose on
the portion of a Co-Located Facility under its operational control at its sole cost and expense; provided, however, each of Pfizer and the Company shall not implement any changes to its operations or conduct any construction or redevelopment
activities at a Co-Located Facility in a manner that could unreasonably interfere with the other party’s operations at such facility, interfere with an on-going Remedial Action conducted by the other party at such facility, or increase the
costs to conduct such Remedial Action. Each of Pfizer and the Company shall provide the other party with written notice sixty (60) days in advance of any such activities that may reasonably be expected to impact the other party’s
operations or an on-going Remedial Action conducted by the other party at such facility. If the other party, in its sole discretion, 

  
 9 

 
believes the notifying party’s proposed plans will negatively impact the other party’s operations or conduct of Remedial Actions at the Co-Located Facility and if it makes a request
within thirty (30) days after receiving notice (or such later time as they mutually agree), the other party shall have the right to confer with the notifying party and propose reasonable alterations to such proposed plans. Each of Pfizer and
the Company, as applicable, shall adopt such reasonable alterations and shall ensure that the construction or redevelopment activities do not materially disrupt, and have no material impacts on, the other party’s operations or the other
party’s conduct of Remedial Actions at a Co-Located Facility. Notwithstanding anything to the contrary in this Environmental Matters Agreement or the Separation Agreement and except as provided in Section 7.05 of this Environmental Matters
Agreement, if each of Pfizer’s and the Company’s change in the industrial/commercial use of a Co-Located Facility as compared to the Facility’s use as of the day before the Effective Date results in a requirement to conduct Remedial
Action (including Remedial Action that is required due to the discovery of historical contamination that would otherwise be the responsibility of the other party), an Environmental Liability, or other Losses, then it shall be solely responsible for
such Remedial Action, Environmental Liability, or Loss and if each of Pfizer’s and the Company’s construction or redevelopment activities results in a requirement to conduct Remedial Action (including Remedial Action that is required due
to the discovery of historical contamination that would otherwise be the responsibility of the other party, unless such contamination is related to constituents of concern being addressed in an on-going Remedial Action conducted by such other party
and is not removed or disturbed during construction or redevelopment activities), an Environmental Liability, or other Losses, then it shall be solely responsible for such Remedial Action, Environmental Liability, or Loss, including, in both cases,
responsibility for any material increases in the costs that result from the party’s disruption to or exacerbation of an on-going Remedial Action or for further Remedial Actions requested after the achievement of a Remedial Action Outcome. For
purposes of this Environmental Matters Agreement, construction or redevelopment activities or changes in the industrial/commercial use of a Facility shall not be construed to include routine maintenance activities that are required to continue to
operate a facility in the same manner and for the same purpose that it was operated before the conduct of the maintenance activity and that are not reasonably expected to have an impact on the operations of the other party or on the conduct of a
Remedial Action at the facility. However, if each of Pfizer or the Company, in conducting such routine maintenance, construction, or redevelopment activities exacerbate any conditions related to an on-going Remedial Action due to its negligence or
willful misconduct, any increases in the costs of the Remedial Action that result from such maintenance, construction, or redevelopment activities shall be the sole responsibility of the party conducting such activities. The parties further agree
that the party conducting the routine maintenance, construction, or redevelopment activities shall be solely responsible for the costs to address the materials or waste generated, impacted, moved, or disturbed as a part of the routine maintenance,
construction or redevelopment. 
 Section 6.07. Liability. Notwithstanding anything to the contrary in this Environmental
Matters Agreement or the Separation Agreement except as provided in Sections 6.06, 7.05, and 

  
 10 

 
9.05 of this Environmental Matters Agreement, each of Pfizer and the Company shall not be liable for any Losses and shall have no obligation to pay Remedial Costs, defend the other party, or
conduct any Remedial Action to the extent the environmental conditions in connection with the Losses or Remedial Costs are discovered in connection with, result from, arise out of, or are the consequence of: (i) any action by or on behalf of
the other party after the Effective Date (including any disclosure, report or other communication from or on behalf of the other party to any Governmental Authority or other third party); (ii) any intrusive investigation, including any
drilling, sampling, testing or monitoring of any soil, surface water, groundwater, or other environmental media conducted by or on behalf of the other party after the Effective Date that was not conducted with respect to a Remedial Action that was
on-going as of the Effective Date; or (iii) changes made by the other party to the industrial/commercial use of the Co-Located Facility after the Effective Date compared to the use of the specific Co-Located Facility as it had been operated by
Pfizer in the twelve (12) months prior to the Effective Date, in each case (under (i), (ii), and (iii)), except to the extent such action, intrusive investigation, report, disclosure, communication, or operational/use change was required to
comply with any requirement under Environmental Law or order of any Governmental Authority. 
 Section 6.08. Disputes.
Any disputes between the parties as to which party is liable for a newly discovered environmental matter shall be resolved pursuant to the provisions of the Separation Agreement, including those addressing allocation of liability (Article II),
mutual releases and indemnification (Article IV) and dispute resolution (Article VIII). Should the parties jointly retain a technical mediator pursuant to the dispute resolution provisions of the Separation Agreement, the mediator shall be
authorized, upon request of the parties, to conduct an investigation, render an opinion, and, if applicable, prepare a proposed apportionment of liability after affording Zoetis Inc. and Pfizer Inc. each the opportunity to submit documentation and
comment on each other’s submissions. 
 Section 6.09. Information Sharing. 

(a) Each of the parties agree to keep the other party reasonably informed of the progress of any Remedial Action it is conducting at a
Co-Located Facility and, upon request by the other party, will provide such party with copies of all related material submissions made to Governmental Authorities related to such Remedial Action. 

(b) Each of Pfizer and the Company shall promptly notify the other party about any information or document directly or indirectly related
to a Remedial Action that the other party is conducting that Pfizer or the Company receives from any Person who is not the other party and shall promptly provide a copy of such information or document to the other party. 

Section 6.10. Mitigation. Each of Pfizer and the Company shall take all reasonable steps to mitigate Losses upon becoming aware of
any event, circumstance, or condition that could reasonably be expected to give rise to a Loss of the other party. 

  
 11 

 Section 6.11. Completion and Post-Closure Maintenance and Monitoring. Each of the
parties’ obligations to conduct Remedial Actions at a facility owned by the other party after the Effective Date shall be deemed complete and fully discharged upon achieving a Remedial Action Outcome and, if such Remedial Action Outcome is
conditioned upon maintenance of the remedy or monitoring of residual contamination, upon payment in full to the other party of the net present value of such post-closure maintenance or monitoring for the duration required by Governmental Authorities
or twenty (20) years, whichever is shorter. Upon receipt of payment in full, the other party shall assume full responsibility for conducting such post-closure maintenance or monitoring in compliance with Environmental Law and at the direction
of the applicable Governmental Authorities. 
 ARTICLE VII 

CATANIA, ITALY 
 Consistent with Article VI of this Environmental Matters Agreement, the parties agree and acknowledge the following with respect to the Company’s Catania Facility: 

Section 7.01. Facility Conditions. The parties acknowledge that prior to the Effective Date, certain constituents of concern were
present in the soil and groundwater beneath the Company’s facility located at Via Franco Gorgone 18, Zona Industriale in Catania, Italy (“Company’s Catania Facility”), as documented by the Catania Remediation Matter
Reports and illustrated in Schedule 7.01 to this Environmental Matters Agreement. 
 Section 7.02. Performance of Remedial
Actions. 
 (a) Pfizer Inc. agrees to perform or cause to be performed the Remedial Actions that are required by national
Environmental Law and agreed upon with Regione Sicilia, Municipality of Catania or ARPA di Catania – Dipartimento Provinciale di Catania pursuant to the work plan that will be authorized by such Governmental Authority (the “Catania
Remediation Matter”) at its sole cost and expense and in a manner that will not unreasonably interfere with the Company’s operations at the Company’s Catania Facility; provided, however, that it is expressly acknowledged
and agreed by the parties that Pfizer may, if approved or permitted by the applicable Governmental Authority or Environmental Law, use Institutional Controls to complete the Remedial Actions. Accordingly, Pfizer shall have sole and exclusive control
of the development, negotiation, implementation and management of such Remedial Actions and, to the extent submissions are required to the Governmental Authorities related to such Remedial Actions, Pfizer will make these submissions in its own name.

 (b) In undertaking the Catania Remediation Matter, Pfizer shall undertake such Remedial Actions in accordance with
Environmental Law, provided that Pfizer may, within 

  
 12 

 
reason, exercise its rights, including, where applicable, its due process right, to contest any requirement imposed, determination made, or action taken by a Governmental Authority with respect
to the Catania Remediation Matter or any contemplated Remedial Actions related thereto. 
 (c) To minimize disruption to the
conduct of operations and Remedial Actions at the Company’s Catania Facility, the parties agree and covenant that: 
  

	 	i.	The Company shall have the right to review, upon request, any and all technical design and relevant engineering specifications of the remedial and monitoring systems
selected by Pfizer that address the Catania Remediation Matter and may provide timely comments to Pfizer, which Pfizer shall reasonably consider, solely with respect to the compatibility of such remedial and monitoring system with the Company’s
current or planned operations at the Company’s Catania Facility. The Company may, at its own expense, hire its own consultants, attorneys or other professionals to monitor Pfizer’s actions to address the Catania Remediation Matter.

  

	 	ii.	To the extent conduct of the Catania Remediation Matter by Pfizer may impact the Company’s current operations at the Company’s Catania Facility, the parties
shall work cooperatively and in good faith to minimize interference with or disruption of such operations. 

  

	 	iii.	The Company shall not take any actions, or fail to act in a way, that could unreasonably interfere with Pfizer’s performance of, increase the costs of, or
exacerbate any conditions related to the Catania Remediation Matter, including communicating with Governmental Authorities in a manner that interferes with, increases the costs of, or is inconsistent with Pfizer’s conduct of the Catania
Remediation Matter. Except for matters addressed in Sections 6.06 and 7.05 of this Environmental Matters Agreement, the Company shall be solely responsible for any material increases in the costs of the Remedial Actions to be performed by Pfizer
that result from actions or inactions that are clearly attributable to the Company or its employees, contractors, or agents. 

  

	 	iv.	The Company shall use due care to protect from damage or destruction any installation, property, or equipment located at the Company’s Catania Facility used in
connection with Pfizer’s conduct of the Catania Remediation Matter, including, any monitoring wells, pumps, and piping. The Company shall reimburse and make Pfizer whole for any damage or destruction done to such installation, property or
equipment, except to the extent such damage is caused by Pfizer, its employees, contractors or agents. 

  
 13 

	 	v.	To the extent required by Environmental Law, the Company shall obtain and maintain in good standing such Governmental Approvals that may be required for Pfizer to
conduct Remedial Actions at the Company’s Catania Facility, including, those for the storage, transportation and off-site disposal of any Hazardous Material generated in the course of addressing the Catania Remediation Matter.

 Section 7.03. Take-Over. The Company shall be entitled to perform, at Pfizer’s reasonable cost and
expense, the Catania Remediation Matter if (i) the Company receives a written notice from Governmental Authorities that reasonably threatens it with the shut-down of all on-site operations due to Pfizer’s failure to perform the Catania
Remediation Matter and (ii) Pfizer does not take actions to resume its performance of the Catania Remediation Matter within sixty (60) days of receiving written notice of such proposed take-over from the Company. In so doing, Pfizer shall
only be liable for such costs that are reasonably required to achieve the applicable Remediation Standard. Where applicable, the Company shall promptly provide copies to Pfizer of all correspondence with the Governmental Authorities, as well as all
work plans, notices, submissions, field work, and draft and final reports that are related to the Catania Remediation Matter. Pfizer may, at its own expense, hire its own consultants, attorneys or other professionals to monitor the Company’s
actions to address the Catania Remediation Matter, including any field work undertaken by the Company. 
 Section 7.04.
Additional Remediation. Notwithstanding other provisions of this Environmental Matters Agreement, to the extent the Company is responsible for remediating any Release of Hazardous Materials at the Company’s Catania Facility, Pfizer, in its
sole discretion, can opt to conduct and control such remediation at the Company’s reasonable expense. In so doing, the Company shall only be liable for such costs that are reasonably required to achieve the applicable Remediation Standard.

 Section 7.05. Construction. The Parties acknowledge that the Remedial Actions that will be conducted, even if
compliant with the applicable Remediation Standard set forth by Environmental Law and even if a Governmental No Further Action Letter is issued, could result in limitations or restrictions related to the use of the Company’s Catania Facility,
including limitations or restrictions related to the current use of the site, or limitations or restrictions related to new construction or development or operational changes at the site. Zoetis Inc. further acknowledges and agrees that it may not
conduct or cause to be conducted any construction or redevelopment activities in the areas marked by hatching on Schedule 7.05 until Pfizer’s obligation to address the Catania Remediation Matter pursuant to this Article and related to the
Liability allocated to it under Article II of the Separation Agreement shall be deemed complete and fully discharged or until Pfizer provides written consent to such construction or redevelopment activities. Zoetis Inc. acknowledges that Pfizer has
the right to refuse to consent to any construction or redevelopment activities in the areas marked by hatching on Schedule 7.05 that may interfere with its achievement of a Remedial Action 

  
 14 

 
Outcome or with its approval plan. Notwithstanding other provisions of this Environmental Matters Agreement, if the Company’s construction or redevelopment activities at any portion of the
Company’s Catania Facility identifies contamination requiring a Remedial Action to be conducted, an Environmental Liability, or other Losses that would otherwise be the responsibility of Pfizer, then Pfizer shall be solely responsible for such
Remedial Action, Environmental Liability, or Loss unless (x) such contamination, Environmental Liability, or Loss was caused after the Effective Date by the negligence or willful misconduct of the Company or its employees, agents,
representatives, contractors, or consultants, or (y) such contamination, Environmental Liability, or Loss was caused by the Company or its employees, agents, representatives, contractors, or consultants after the Effective Date, or
(z) such contamination, Environmental Liability, or Loss was caused by a Release of Hazardous Materials after the Effective Date at real property neither owned nor operated by Pfizer. The Company shall, however, remain responsible for the costs
to address the materials or waste generated, impacted, moved, or disturbed as a part of the construction or redevelopment activities and the costs associated with obtaining or complying with any Governmental Authorizations necessary to conduct such
construction or redevelopment activities. The Company shall: 
  

	 	i.	ensure that any construction and redevelopment activities or changes in operations minimize any disruption to or exacerbation of the Catania Remediation Matter;

  

	 	ii.	take into account potential indoor air inhalation and, as appropriate, incorporate reasonable measures to prevent exposure to vapors, including without limitation,
sub-slab vapor collection systems, impermeable flooring and other measures as necessary; and 

  

	 	iii.	comply with Pfizer Catania Facility SOP 514 and 515 in connection with all sub-grade construction activities. 

Section 7.06. Indoor Flooring. The Company is responsible for conducting periodic inspections and maintenance of all indoor
flooring in buildings and structures at the Company’s Catania Facility. The Company shall maintain such flooring in good working condition and in a manner that minimizes indoor air inhalation risks from vapor intrusion. The Company is solely
responsible for any Remedial Actions that may be required under Environmental Law due to indoor air inhalation risks from vapor intrusion in buildings and structures at the Company’s Catania Facility to the extent it results from the
Company’s failure to maintain the integrity of such flooring to eliminate or mitigate vapor intrusion pathways. 

Section 7.07. Waste Water Treatment Facility. Pursuant to the Site Services Agreement, the Company will operate the on-site waste
water treatment facility and shall permit Pfizer to discharge waste water associated with the Catania Remediation Matter to and through such facility as long as such waste water does not interfere with the Company’s operation of the waste water
treatment facility or its compliance with Environmental Law or any Governmental Authorizations issued thereunder. 

  
 15 

 ARTICLE VIII 
 KALAMAZOO, MICHIGAN (SOUTH CAMPUS) 
 Consistent with Article VI of
this Environmental Matters Agreement, the parties agree and acknowledge the following with respect to Pfizer’s Kalamazoo Facility and the Company’s South Campus Kalamazoo Facility: 

Section 8.01. Facility Conditions. 
 (a) The parties acknowledge that prior to the Effective Date, certain constituents of concern were present in groundwater beneath Pfizer’s facility located at 700 Portage Road in Kalamazoo, Michigan
(“Pfizer’s Kalamazoo Facility”) above Michigan’s generic groundwater cleanup criteria, as documented by the Kalamazoo Environmental Matter Report (the “Kalamazoo Environmental Matter”). Pfizer is presently
conducting Remedial Actions at the site to address the Kalamazoo Environmental Matter with oversight from the Michigan Department of Environmental Quality. 
 (b) The parties further acknowledge that such groundwater impacts do not extend to the Company’s facility located at 7725 Portage Road, Portage, Michigan 49002 in Kalamazoo, Michigan
(“Company’s South Campus Kalamazoo Facility”); however, certain Remedial Actions are taking place at such facility to address the Kalamazoo Environmental Matter. 

Section 8.02. Performance of Remedial Actions. 
 (a) Pfizer shall continue to perform the Remedial Actions at Pfizer’s Kalamazoo Facility and, to the extent necessary, at the Company’s South Campus Kalamazoo Facility that are required pursuant
to Environmental Law or by Governmental Authorities to address the Kalamazoo Environmental Matter at Pfizer’s sole cost and expense, and in a manner that will not unreasonably interfere with the Company’s operations at the Company’s
South Campus Kalamazoo Facility; provided, however, that it is expressly acknowledged and agreed by the parties that Pfizer may, if approved or permitted by the applicable Governmental Authority or Environmental Law, use Institutional
Controls to complete the Remedial Actions. Accordingly, Pfizer shall have sole and exclusive control of the development, negotiation, implementation, and management of such Remedial Actions and, to the extent submissions are required to the
Governmental Authorities related to such Remedial Actions, Pfizer will make these submissions in its own name. 
 (b) In
undertaking Remedial Actions to address the Kalamazoo Environmental Matter, Pfizer shall act in accordance with Environmental Law; provided that Pfizer may, within reason, exercise its rights, including, where applicable, its due process
right, to contest any requirement imposed, determination made, or action taken by a Governmental Authority with respect to the Kalamazoo Remediation Matter or any contemplated Remedial Actions related thereto. 

  
 16 

 (c) To minimize disruption to the conduct of operations and Remedial Actions at the
Company’s South Campus Kalamazoo Facility, the parties agree and covenant that: 
  

	 	i.	The Company shall have the right to review, upon request, any and all technical design and relevant engineering specifications of the remedial and monitoring systems
selected by Pfizer that address the Kalamazoo Environmental Matter and may provide timely comments to Pfizer, which Pfizer shall reasonably consider, solely with respect to the compatibility of such remedial and monitoring system with the
Company’s current or planned operations at the Company’s South Campus Kalamazoo Facility. The Company may, at its own expense, hire its own consultants, attorneys or other professionals to monitor Pfizer’s actions on the
Company’s South Campus Kalamazoo Facility to address the Kalamazoo Environmental Matter. 

  

	 	ii.	To the extent conduct of the Kalamazoo Environmental Matter by Pfizer may impact the Company’s current operations at the Company’s South Campus Kalamazoo
Facility, the parties shall work cooperatively and in good faith to minimize interference with or disruption of such operations. 

  

	 	iii.	The Company shall not take any actions, or fail to act in a way, that could unreasonably interfere with Pfizer’s performance of, increase the costs of, or
exacerbate any conditions related to the Kalamazoo Environmental Matter, including communicating with Governmental Authorities in a manner that interferes with, increases the costs of, or is inconsistent with Pfizer’s conduct of the Kalamazoo
Environmental Matter. Except for matters addressed in Section 6.06 of this Environmental Matters Agreement, the Company shall be solely responsible for any material increases in the costs of the Remedial Actions to be performed by Pfizer that
result from actions or inactions that are clearly attributable to the Company or its employees, contractors, or agents. 

  

	 	iv.	The Company shall protect from damage or destruction any installation, property, or equipment located at the Company’s South Campus Kalamazoo Facility used in
connection with Pfizer’s conduct of the Kalamazoo Environmental Matter, including, any monitoring wells, pumps, and piping. The Company shall reimburse and make Pfizer whole for any damage or destruction done to such installation, property or
equipment, except to the extent such damage is caused by Pfizer, its employees, contractors or agents. 

  

	 	v.	To the extent required by Environmental Law, the Company shall obtain and maintain in good standing such Governmental Approvals that may be required for Pfizer to
conduct Remedial Actions at the Company’s South Campus Kalamazoo Facility, including, those for the storage, transportation and off-site disposal of any Hazardous Material generated in the course of addressing the Kalamazoo Environmental
Matter. 

  
 17 

 Section 8.03. Compliance. 

(a) Zoetis Inc. acknowledges that it has due care obligations and agrees to comply and cause members of its Group to comply with
Michigan’s due care obligations as set forth in Part 201 of the Michigan Natural Resources and Environmental Protection Act, Act 451 of 1994, as amended. 
 (b) The Company shall comply with the terms of the restrictive covenant that was executed by Pharmacia & Upjohn Company LLC with the Kalamazoo County Register of Deeds in connection with the
Company’s South Campus Kalamazoo Facility that was recorded on September 27, 2012. The parties agree that the terms of this restrictive covenant are not inconsistent with Section 4.02(c) of this Environmental Matters Agreement and
shall not be considered to be more than the least stringent, most cost effective Remediation Standard or remedy as further described in this Section 4.02(c). 
 ARTICLE IX 
 GUARULHOS, BRAZIL 

Consistent with Article VI of this Environmental Matters Agreement, the parties agree and acknowledge the following with respect to
Guarulhos Leased Facility: 
 Section 9.01. Facility Conditions. The parties acknowledge that in connection with the
former divestiture of a portion of the Company’s facility in Guarulhos, Brazil pursuant to an Asset Purchase Agreement by and between Pfizer Inc. and Philipp Brothers Chemicals, Inc. dated September 28, 2000, Pfizer Inc. retained liability
that it subsequently transferred to the Company pursuant to the Separation Agreement for the remediation of certain soil and groundwater impacts at the Company’s facility located at Avenida Presidente Tancredo de Almeida Neves, 1555, Vila
Sant’Anna in Guarulhos, Brazil that it is leasing to a member of the Pfizer Group (“Guarulhos Leased Facility”) pursuant to the Private Instrument of Non-residential Lease Agreement and Others, the impacts and of which have
been documented in the Guarulhos Remediation Matter Reports (the “Guarulhos Remediation Matter”). 

Section 9.02. Performance of Remedial Actions. 
 (a) Zoetis Inc. agrees to perform or cause to be performed the Remedial Actions that are required by CETESB – Companhia Ambiental do Estado de São Paulo to address the Guarulhos
Remediation Matter at its sole cost and expense and in a manner that will not unreasonably interfere with Pfizer’s operations at the Guarulhos Leased Facility; provided, however, that it is

  
 18 

 
expressly acknowledged and agreed by the parties that the Company may, if approved or permitted by the applicable Governmental Authority or Environmental Law, use Institutional Controls to
complete the Remedial Actions. Accordingly, the Company shall have sole and exclusive control of the development, negotiation, implementation and management of such Remedial Actions and, to the extent submissions are required to the Governmental
Authorities related to such Remedial Actions, the Company will make these submissions in its own name. 
 (b) In undertaking
Remedial Actions to address the Guarulhos Remediation Matter, the Company shall undertake such Remedial Actions in accordance with Environmental Law, provided that the Company may, within reason, exercise its rights, including, where
applicable, its due process right, to contest any requirement imposed, determination made, or action taken by a Governmental Authority with respect to the Guarulhos Remediation Matter or any contemplated Remedial Actions related thereto. 

(c) To minimize disruption to the conduct of operations and Remedial Actions at the Guarulhos Leased Facility, the parties agree and
covenant that: 
  

	 	i.	During the Lease Term, Pfizer shall have the right to review, upon request, any and all technical design and relevant engineering specifications of the remedial and
monitoring systems selected by the Company that address the Guarulhos Remediation Matter and may provide timely comments to the Company, which the Company shall reasonably consider, with respect to the compatibility of such remedial and monitoring
system with Pfizer’s current or planned operations at the Guarulhos Leased Facility. Pfizer may, at its own expense, hire its own consultants, attorneys or other professionals to monitor the Company’s actions to address the Guarulhos
Remediation Matter. 

  

	 	ii.	To the extent the Company’s conduct of Remedial Actions to address the Guarulhos Remediation Matter may impact Pfizer’s current operations at the Guarulhos
Leased Facility, the parties shall work cooperatively and in good faith to minimize interference with or disruption of such operations. 

  

	 	iii.	Pfizer shall not take any actions, or fail to act in a way, that could unreasonably interfere with the Company’s performance of, increase the costs of, or
exacerbate any conditions related to the Guarulhos Remediation Matter, including communicating with Governmental Authorities in a manner that interferes with, increases the costs of, or is inconsistent with the Company’s conduct of the
Guarulhos Remediation Matter. Except for matters addressed in Sections 6.06 and 9.05 of this Environmental Matters Agreement, Pfizer shall be solely responsible for any material increases in the costs of the Remedial Actions to be performed by the
Company that result from actions or inactions that are clearly attributable to Pfizer or its employees, contractors, or agents. 

  
 19 

	 	iv.	During the Lease Term, Pfizer shall use due care to protect from damage or destruction any installation, property, or equipment located at the Guarulhos Leased Facility
used in connection with the Company’s conduct of Remedial Actions to address the Guarulhos Remediation Matter, including, any monitoring wells, pumps, and piping. Pfizer shall reimburse and make the Company whole for any damage or destruction
done to such installation, property or equipment, except to the extent such damage is caused by the Company, its employees, contractors or agents. 

  

	 	v.	During the Lease Term and to the extent required by Environmental Law, Pfizer shall obtain and maintain in good standing such Governmental Approvals that may be
required for the Company to conduct Remedial Actions at the Guarulhos Leased Facility, including those for the storage, transportation and off-site disposal of any Hazardous Material generated in the course of addressing the Guarulhos Remediation
Matter. 

 Section 9.03. Take-Over. Pfizer shall be entitled to perform, at the Company’s
reasonable cost and expense, Remedial Actions to address the Guarulhos Remediation Matter if (i) Pfizer receives a written notice from Governmental Authorities that reasonably threatens it with the shut-down of all on-site operations due to the
Company’s failure to perform Remedial Actions to address the Guarulhos Remediation Matter or (ii) the Company has not completed its substitution for Pfizer with Governmental Authorities relating to the Guarulhos Remediation Matter and
Pfizer receives a written notice from Governmental Authorities demanding that it perform Remedial Actions to address the Guarulhos Remediation Matter because of the Company’s failure to do so. In both cases, Pfizer shall only be entitled to
perform such Remedial Actions if the Company does not take actions to resume its performance of Remedial Actions within sixty (60) days of receiving written notice of such proposed take-over from Pfizer. In so doing, the Company shall only be
liable for such costs that are reasonably required to achieve the applicable Remediation Standard. Where applicable, Pfizer shall promptly provide copies to the Company of all correspondence with the Governmental Authorities, as well as all work
plans, notices, submissions, field work, and draft and final reports that are related to the Guarulhos Remediation Matter. The Company may, at its own expense, hire its own consultants, attorneys or other professionals to monitor Pfizer’s
actions to address the Guarulhos Remediation Matter, including any field work undertaken by Pfizer. 
 Section 9.04.
Additional Remediation. Notwithstanding other provisions of this Environmental Matters Agreement, to the extent Pfizer is responsible for remediating any Release of Hazardous Materials at the Guarulhos Leased Facility during the Lease Term, the
Company, in its sole discretion, can opt to conduct and control such remediation at Pfizer’s reasonable expense. In so doing, Pfizer shall only be liable for such costs that are reasonably required to achieve the applicable Remediation
Standard. 

  
 20 

 Section 9.05. Construction. The Parties acknowledge that the Remedial Actions
that will be conducted, even if compliant with the applicable Remediation Standard set forth by Environmental Law and even if a Governmental No Further Action Letter is issued, could result in limitations or restrictions related to the use of the
Guarulhos Leased Facility, including limitations or restrictions related to the current use of the site, or limitations or restrictions related to new construction or development or operational changes at the site. Pfizer Inc. further acknowledges
and agrees that it may not conduct or cause to be conducted any construction or redevelopment activities in the areas marked by hatching on Schedule 9.05 until the Company receives a Remedial Action Outcome for the Guarulhos Remediation Matter or
until the Company provides written consent to such construction or redevelopment activities. Pfizer Inc. acknowledges that the Company has the right to refuse to consent to any construction or redevelopment activities in the areas marked by hatching
on Schedule 7.05 that may interfere with its achievement of a Remedial Action Outcome or with its approval plan. During the Lease Term, Pfizer shall ensure that any construction and redevelopment activities or change in operations minimize any
disruption to the Company’s Remedial Actions or exacerbation of the Guarulhos Remediation Matter. 
 Section 9.06.
Compliance. During the Lease Term, Pfizer shall comply in all material aspects with all Environmental Laws applicable to its operations at the Guarulhos Leased Facility and shall be responsible for obtaining and maintaining in full force and
effect for the full duration of the Lease Term all Governmental Authorizations required to conduct its operations in such compliance. 
 Section 9.07. Waste Water Treatment Facility. Upon completion of construction of the on-site waste water treatment facility, Pfizer shall be permitted to operate, as needed, and discharge
waste water associated with its operations to and through such facility as long as such waste water does not interfere with the operation of the waste water treatment facility or its compliance with Environmental Law or any Governmental
Authorizations issued thereunder. 
 ARTICLE X 
 KALAMAZOO, MICHIGAN (BUILDING 248) 
 Consistent with Article VI of
this Environmental Matters Agreement, the parties agree and acknowledge the following with respect to the Kalamazoo Building 248 Facility: 
 Section 10.01. Lease. The parties acknowledge that after the Effective Date a member of the Pfizer Group will be leasing and operating a portion of the Company’s facility located at 2605
East Kilgore Road in Kalamazoo, Michigan (“Kalamazoo Building 248 Facility”) pursuant to the Lease Agreement between PAH P&U LLC and Pharmacia & Upjohn Company LLC. 

  
 21 

 Section 10.02. Compliance. During the Lease Term, Pfizer, in conducting its
operations under the Lease, shall comply in all material aspects with all Environmental Laws applicable to such operations at the Kalamazoo Building 248 Facility and shall be responsible for obtaining and maintaining in full force and effect for the
full duration of the Lease Term all Governmental Authorizations required for Pfizer to conduct its operations under the Lease. 

ARTICLE XI 

TERMINATION 
 Section 11.01. Termination. This Environmental Matters Agreement will be terminated automatically if the Separation Agreement has been terminated pursuant to Article X of the Separation
Agreement. 
 Section 11.02. Effect of Termination. In the event of any termination of this Environmental Matters
Agreement, no party to this Environmental Matters Agreement (or any of its directors, officers, members or managers) shall have any Liability or further obligation to any other party. 

ARTICLE XII 
 MISCELLANEOUS 
 Section 12.01. Notifications. All
notices or other communications under this Environmental Matters Agreement or related to environmental matters under the Separation Agreement, including, but not limited to tenders of new Environmental Liabilities and requests for Information, shall
be in writing and shall be deemed to be duly given when (a) delivered in person or (b) deposited in the United States mail or private express mail, postage prepaid, addressed as follows: 

If to Pfizer, to: 

Pfizer Inc. 
 235
East 42nd Street 
 New York, NY 10017 
 Attention: 

  
 22 

 with a copy to: 
 [—] 
 If to the Company to:

 Zoetis Inc. 
 [—] 
 with a copy to: 

[—] 
 Any party may, by notice to the other party, change the address to which such notices are to be given. 
 Section 12.02. Disputes. All disputes between the parties shall be subject to the provisions of Article VIII of the Separation Agreement and Section 6.08 of this Environmental Matters
Agreement. 
 Section 12.03. Assignability. Except as otherwise provided in the Separation Agreement, this
Environmental Matters Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns; provided, however, that no party hereto may assign its respective rights or delegate
its respective obligations under this Environmental Matters Agreement without the express prior written consent of the other party or parties hereto. 
 Section 12.04. Cooperation. The parties agree to cooperate and deal in good faith to implement this Environmental Matters Agreement. 

Section 12.05. Compliance with Laws. The parties shall, in the implementation of this Environmental Matters Agreement,
materially comply with all applicable Laws. 
 Section 12.06. Conflict of Terms. This Environmental Matters
Agreement governs Pfizer’s and the Company’s conduct with respect to certain allocated Liabilities. In the event of a conflict between this Environmental Matters Agreement and the Separation Agreement, the Environmental Matters Agreement
shall control with respect to the subject matter hereof. Environmental Permit Transfer Agreements executed in contemplation of the separation of the Animal Health Business from the other businesses conducted by Pfizer and its Subsidiaries shall not
alter or affect the terms and conditions of this Environmental Matters Agreement, the Separation Agreement, or any other Ancillary Agreements. 

  
 23 

 Section 12.07. Governing Law. This Environmental Matters Agreement shall be
governed by and construed and interpreted in accordance with the Laws of the State of New York, without regard to the conflict of laws principles thereof that would result in the application of any Law other than the Laws of the State of New York.

 Section 12.08. Severability. If any provision of this Environmental Matters Agreement or the application thereof
to any Person or circumstance is determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions hereof or the application of such provision to Persons or circumstances or in jurisdictions other than
those as to which it has been held invalid or unenforceable, shall remain in full force and effect and shall in no way be affected, impaired or invalidated thereby. 
 Section 12.09. Interpretation. Words in the singular shall be held to include the plural and vice versa and words of one gender shall be held to include the other genders as the context
requires. The terms “hereof”, “herein” and “herewith” and words of similar import shall, unless otherwise stated, be construed to refer to this Environmental Matters Agreement as a whole (including all of the schedules,
exhibits and appendices hereto) and not to any particular provision of this Environmental Matters Agreement. Article, Section, Exhibit, Schedule and Appendix references are to the Articles, Sections, Exhibits, Schedules and Appendices to this
Environmental Matters Agreement unless otherwise specified. The word “including” and words of similar import when used in this Environmental Matters Agreement shall mean “including, without limitation,” unless the context
otherwise requires or unless otherwise specified. The terms “written request,” “written consent,” and “written notice” shall be construed to include a request, consent, or notice that is communicated via electronic
means. 
 Section 12.10. Headings. The article, section, and paragraph headings contained in this Environmental
Matters Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Environmental Matters Agreement. 
 Section 12.11. Specific Performance. In the event of any actual or threatened default in, or breach of, any of the terms, conditions and provisions of this Environmental Matters Agreement, the
party or parties who are or are to be thereby aggrieved shall have the right to specific performance and injunctive or other equitable relief of its rights under this Environmental Matters Agreement, in addition to any and all other rights and
remedies at law or in equity, and all such rights and remedies shall be cumulative. 
 Section 12.12. Incorporation by
Reference. Unless otherwise addressed in this Article XII of the Environmental Matters Agreement, the provisions of Article XI of the Separation Agreement shall be incorporated by reference herein. 

  
 24 

 IN WITNESS WHEREOF, the parties have caused this Environmental Matters Agreement to
be executed by their duly authorized representatives. 
  

			
	PFIZER INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	ZOETIS INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 25Form of Registration Rights Agreement

 Exhibit 10.15 
 FORM OF REGISTRATION RIGHTS AGREEMENT 
 This REGISTRATION RIGHTS AGREEMENT,
dated as of _________, _____ (this “Agreement”), is by and between Zoetis Inc., a Delaware corporation (“Zoetis”), and Pfizer Inc., a Delaware corporation (“Pfizer”). 

WHEREAS, Pfizer currently owns all of the issued and outstanding shares of Class A common stock, par value $0.01 per share, of
Zoetis (“Zoetis Class A Common Stock”) and Class B common stock, par value $0.01 per share, of Zoetis (“Zoetis Class B Common Stock” and together with the Zoetis Class A Common Stock, the “Zoetis
Common Stock”); 
 WHEREAS, Pfizer intends to transfer shares of Class A Common Stock to the Debt Exchange Parties
in exchange for certain debt obligations of Pfizer held by the Debt Exchange Parties as principals for their own account (the “Debt Exchange”); 
 WHEREAS, Pfizer intends for an offer and sale to the public of shares of Class A Common Stock transferred in the Debt Exchange (the “IPO”) to take place pursuant to a registration
statement on Form S-1 (the “IPO Registration Statement”); 
 WHEREAS, after the IPO, transfer shares of Zoetis
Common Stock to holders of shares of Pfizer’s common stock by means of one or more distributions by Pfizer to holders of Pfizer’s common stock of shares of Zoetis Common Stock, one or more offers to holders of Pfizer’s common stock to
exchange their Pfizer’s common stock for shares of Zoetis Common Stock, or any combination thereof (the “Distribution”); 
 WHEREAS, from time to time prior to the Distribution, Pfizer may enter into a private exchange with one or more Participating Banks pursuant to which such Participating Banks shall exchange Debt
Securities with Pfizer for some or all of the Registrable Securities (a “Private Debt Exchange”), and such Participating Banks may sell or offer to sell such Registrable Securities in one or more transactions Registered under the
Securities Act; 
 WHEREAS, from time to time, Pfizer may sell or offer to sell some or all of the outstanding shares of Zoetis
Common Stock then owned directly or indirectly by Pfizer, in one or more transactions Registered under the Securities Act; and 

WHEREAS, Zoetis desires to grant to Pfizer the Registration Rights for the Registrable Securities, subject to the terms and conditions of
this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing and the mutual promises, covenants and agreements of the
parties hereto, and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

 ARTICLE I 
 DEFINITIONS 
 1.1 Defined Terms. As used in this Agreement, the following
terms shall have the following meanings: 
 “Action” means any demand, action, suit, countersuit, arbitration,
inquiry, proceeding or investigation by or before any federal, state, local, foreign or international Governmental Authority or any arbitration or mediation tribunal. 
 “Affiliate” shall mean, when used with respect to a specified Person, another Person that controls, is controlled by, or is under common control with the Person specified;
provided, however, that, for purposes of this Agreement, Zoetis and its Subsidiaries shall not be considered to be “Affiliates” of Pfizer and its Subsidiaries (other than Zoetis and its Subsidiaries), and Pfizer and its
Subsidiaries (other than Zoetis and its Subsidiaries) shall not be considered to be “Affiliates” of Zoetis or its Subsidiaries. As used herein, “control” means the possession, directly or indirectly, of the power to direct
or cause the direction of the management and policies of such person, whether through the ownership of voting securities or other interests, by contract or otherwise. 
 “Agreement” has the meaning set forth in the preamble to this Agreement. 
 “Business Day” shall mean any day that is not a Saturday, Sunday or other day on which banking institutions doing business in New York, New York are authorized or obligated by law or
required by executive order to be closed. 
 “Convertible or Exchange Registration” has the meaning set forth
in Section 2.8. 
 “Debt Exchange” has the meaning set forth in the recitals to this Agreement.

 “Debt Exchange Parties” means certain of the underwriters in the IPO or their Affiliates that exchange for
debt obligations of Pfizer for Zoetis Class A Common Stock. 
 “Debt Securities” means debt instruments or
securities issued by Pfizer. 
 “Demand Registration” has the meaning set forth in Section 2.1(a).

 “Distribution” has the meaning set forth in the recitals to this Agreement. 

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and any successor thereto, and any rules and
regulations promulgated thereunder, all as the same shall be in effect from time to time. 
 “Governmental
Authority” means any nation or government, any state, municipality or other political subdivision thereof, and any entity, body, agency, commission, department, board, bureau, court, tribunal or other instrumentality, whether federal,
state, local, domestic, foreign or multinational, exercising executive, legislative, judicial, regulatory, administrative or other similar functions of, or pertaining to, government and any executive official thereof. 

  
 2 

 “Holder” shall mean Pfizer or any of its Subsidiaries, so long as such
Person holds any Registrable Securities, and any Person owning Registrable Securities who is a permitted transferee of rights under Section 3.3. 
 “Initiating Holder” has the meaning set forth in Section 2.1(a). 
 “IPO” has the meaning set forth in the recitals to this Agreement. 
 “IPO Registration Statement” has the meaning set forth in the recitals to this Agreement. 
 “Loss” or “Losses” has the meaning set forth in Section 2.10(a). 
 “Participating Banks” shall mean such investment banks that engage in any Private Debt Exchange with Pfizer. 
 “Person” means any individual, firm, limited liability company or partnership, joint venture, corporation, joint stock company, trust or unincorporated organization, incorporated or
unincorporated association, government (or any department, agency or political subdivision thereof) or other entity of any kind, and shall include any successor (by merger or otherwise) of such entity. 

“Pfizer” has the meaning set forth in the preamble to this Agreement and shall include its successors, by merger,
acquisition, reorganization or otherwise. 
 “Piggyback Registration” has the meaning set forth in
Section 2.2(a). 
 “Private Debt Exchange” has the meaning set forth in the recitals to this
Agreement. 
 “Prospectus” means the prospectus included in any Registration Statement, all amendments and
supplements to such prospectus, including post-effective amendments, and all other material incorporated by reference in such prospectus. 
 “Registrable Securities” means any Shares and any securities issued or issuable directly or indirectly with respect to, in exchange for, upon the conversion of or in replacement of the
Shares, whether by way of a dividend or distribution or stock split or in connection with a combination of shares, recapitalization, merger, consolidation, exchange or other reorganization. For the avoidance of doubt, subject to the following
sentence, the term “Registrable Securities” includes, Zoetis Class A Common Stock, Zoetis Class B Common Stock and any shares of Zoetis Class A Common Stock issued upon the conversion of Zoetis Class B Common Stock. The
term “Registrable Securities” excludes, however, any security (i) the sale of which has been effectively Registered under the Securities Act and which has been disposed of in accordance with a Registration Statement,
(ii) that have been sold or disposed of pursuant to Rule 144 (or any successor provision) under the Securities Act, (iii) that may be sold pursuant to Rule 144 (or any successor provision) under the Securities Act without being subject to
the volume limitations in subsection (e) of such rule or (iv) that have been sold by a Holder in a transaction in which such Holder’s rights under this Agreement are not, or cannot be, assigned. 

  
 3 

 “Registration” means a registration with the SEC of the offer and sale to
the public of Zoetis Common Stock under a Registration Statement. The terms “Register,” “Registered” and “Registering” shall have a correlative meaning. 

“Registration Expenses” shall mean all expenses incident to Zoetis’s performance of or compliance with this
Agreement, including all (i) registration, qualification and filing fees; (ii) expenses incurred in connection with the preparation, printing and filing under the Securities Act of the Registration Statement, any Prospectus and any issuer
free writing prospectus and the distribution thereof; (iii) the fees and expenses of the Company’s counsel and independent accountants; (iv) the reasonable fees and expenses of not more than one firm of attorneys acting as legal
counsel for all of the Holders in the relevant Registration and sale; (v) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Shares under the state or
foreign securities or blue sky laws and the preparation, printing and distribution of a Blue Sky Memorandum (including the related fees and expenses of counsel); (vi) the costs and charges of any transfer agent and any registrar; (vii) all
expenses and application fees incurred in connection with any filing with, and clearance of an offering by, Financial Industry Regulatory Authority, Inc.; (viii) expenses incurred in connection with any “road show” presentation to
potential investors; (ix) printing expenses, messenger, telephone and delivery expenses; (x) internal expenses of Zoetis (including all salaries and expenses of employees of Zoetis performing legal or accounting duties); and (xi) fees
and expenses of listing any Registrable Securities on any securities exchange on which shares of Zoetis Common Stock are then listed; but excluding any internal expenses of the Holder, any underwriting discounts or commissions attributable to the
sale of any Registrable Securities and any stock transfer taxes. 
 “Registration Period” has the meaning set
forth in Section 2.1(c). 
 “Registration Rights” shall mean the rights of the Holders to cause
Zoetis to Register Registrable Securities pursuant to this Agreement. 
 “Registration Statement” means any
registration statement of Zoetis filed with, or to be filed with, the SEC under the rules and regulations promulgated under the Securities Act, including the related Prospectus, amendments and supplements to such registration statement, including
post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement. 

“Registration Suspension” has the meaning set forth in Section 2.1(d). 

“SEC” has the meaning set forth in the recitals to this Agreement. 

“Securities Act” means the U.S. Securities Act of 1933, as amended, and any successor thereto, and any rules and
regulations promulgated thereunder, all as the same shall be in effect from time to time. 

  
 4 

 “Shares” means all shares of Zoetis Common Stock that are beneficially
owned by Pfizer or any permitted transferee from time to time, whether or not held immediately following the IPO. 

“Shelf Registration” means a Registration Statement of Zoetis for an offering to be made on a delayed or continuous
basis of Zoetis Common Stock pursuant to Rule 415 under the Securities Act (or similar provisions then in effect). 

“Subsidiary” shall mean, with respect to any Person, any corporation, limited liability company, joint venture or
partnership of which such Person (i) beneficially owns, either directly or indirectly, more than fifty percent (50%) of (A) the total combined voting power of all classes of voting securities of such Person, (B) the total
combined equity interests or (C) the capital or profit interests, in the case of a partnership, or (ii) otherwise has the power to vote, either directly or indirectly, sufficient securities to elect a majority of the board of directors or
similar governing body. 
 “Takedown Notice” has the meaning set forth in Section 2.1(g).

 “Underwritten Offering” means a Registration in which securities of Zoetis are sold to an underwriter or
underwriters on a firm commitment basis for reoffering to the public. 
 “Zoetis” has the meaning set forth in
the preamble to this Agreement and shall include its successors, by merger, acquisition, reorganization or otherwise. 

“Zoetis Common Stock” has the meaning set forth in the recitals to this Agreement. 

“Zoetis Class A Common Stock” has the meaning set forth in the recitals to this Agreement. 

“Zoetis Class B Common Stock” has the meaning set forth in the recitals to this Agreement. 

“Zoetis Public Sale” has the meaning set forth in Section 2.2(a). 

“Zoetis Notice” has the meaning set forth in Section 2.1(a). 

“Zoetis Takedown Notice” has the meaning set forth in Section 2.1(g). 

 

	1.2	General Interpretive Principles. Whenever used in this Agreement, except as otherwise expressly provided or unless the context otherwise requires, any noun or
pronoun shall be deemed to include the plural as well as the singular and to cover all genders. Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be
deemed to be followed by the words “without limitation.” Unless otherwise specified, the terms “hereof,” “herein,” “hereunder” and similar terms refer to this Agreement as a whole
(including the exhibits hereto), and references herein to Articles and Sections refer to Articles and Sections of this Agreement. Except as otherwise indicated, all periods of time referred to herein shall include all Saturdays, Sundays and
holidays; provided, however, that if the date to perform the act or give any notice with respect to this Agreement shall fall on a day other than a Business Day, 

  
 5 

 
such act or notice may be performed or given timely if performed or given on the next succeeding Business Day. References to a Person are also to its permitted successors and assigns. The parties
have participated jointly in the negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the parties, and no presumption or
burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement. 

ARTICLE II 

REGISTRATION RIGHTS 
 2.1 Registration. 
 (a) Request. Any Holder(s) of Registrable
Securities (collectively, the “Initiating Holder”) shall have the right to request that Zoetis file a Registration Statement with the SEC on the appropriate registration form for all or part of the Registrable Securities held by
such Holder once such Registrable Securities are no longer subject to the underwriter lock-up applicable to the IPO (which may be due to the expiration or waiver of such lock-up with respect to such Registrable Securities) by delivering a written
request to Zoetis specifying the number of shares of Registrable Securities such Holder wishes to Register (a “Demand Registration”). Zoetis shall (i) within five (5) days of the receipt of such request, give written
notice of such Demand Registration to all Holders of Registrable Securities (the “Zoetis Notice”), (ii) use its reasonable best efforts to file a Registration Statement in respect of such Demand Registration within forty-five
(45) days of receipt of the request, and (iii) use its reasonable best efforts to cause such Registration Statement to become effective as expeditiously as possible. Zoetis shall include in such Registration all Registrable Securities that
the Holders request to be included within the ten (10) days following their receipt of the Zoetis Notice. 
 (b)
Limitations of Demand Registrations. There shall be no limitation on the number of Demand Registrations pursuant to Section 2.1(a); provided, however, that the Holders may not require Zoetis to effect more than
two (2) Demand Registrations in a twelve (12)-month period (it being understood that the IPO Registration Statement shall not be treated as a Demand Registration). In the event that any Person shall have received rights to Demand Registrations
pursuant to Section 2.7 or Section 3.3, and such Person shall have made a Demand Registration request, such request shall be treated as having been made by the Holder(s); provided, however, that if Pfizer and
its Subsidiaries engage in up to three (3) related Private Debt Exchanges within any six (6)-month period following the date hereof, the Demand Registration requests made by the Participating Banks in such Private Debt Exchanges pursuant to its
registration rights agreements with Zoetis shall collectively only count as one (1) Demand Registration for purposes of the limitation on the number of Demand Registration set forth in the first sentence of this Section 2.1(b) and
such Demand Registration shall be deemed to have occurred upon the filing of the then most recent applicable Registration Statement; provided that the proceeding proviso shall not limit the number of Private Debt Exchanges that Pfizer and its
Subsidiaries may engage in or the period over which they may engage in Private Debt Exchanges, but is solely intended to govern the treatment of such Private Debt Exchanges for purposes of the limitations on Demand Registrations in this
Section 2.1(b). The Registrable Securities requested to be Registered pursuant to Section 2.1(a) must represent (i) an aggregate offering price of Registrable Securities that is reasonably be expected to equal at least
$[            ] or (ii) all of the remaining Registrable Securities owned by the requesting Holder and its Affiliates. 

  
 6 

 (c) Effective Registration. Zoetis shall be deemed to have effected a Registration
for purposes of Section 2.1(b) if the Registration Statement is declared effective by the SEC or becomes effective upon filing with the SEC, and remains effective until the earlier of (i) the date when all Registrable Securities
thereunder have been sold and (ii) ninety (90) days from the effective date of the Registration Statement (the “Registration Period”). No Registration shall be deemed to have been effective if the conditions to closing
specified in the underwriting agreement, if any, entered into in connection with such Registration are not satisfied by reason of Zoetis . If, during the Registration Period, such Registration is interfered with by any Registration Suspension, stop
order, injunction or other order or requirement of the SEC or other Governmental Agency, the Registration Period shall be extended on a day-for-day basis for any period the Holder is unable to complete an offering as a result of such Registration
Suspension, stop order, injunction or other order or requirement of the SEC or other Governmental Agency. 
 (d) Delay in
Filing; Suspension of Registration. If the filing, initial effectiveness or continued use of a Registration Statement would, as reasonably determined in good faith by Zoetis, require the disclosure of material non-public information that Zoetis
has a bona fide business purpose to keep confidential and the disclosure of which would have a material adverse effect on any active proposal by Zoetis or any of its Subsidiaries to engage in any material acquisition, merger, consolidation,
tender offer, other business combination, reorganization or other material transaction, Zoetis may, upon giving prompt written notice of such action to the Holders, postpone the filing or effectiveness of such Registration
(a “Registration Suspension”) for a period not to exceed thirty (30) days; provided, however, that Zoetis may exercise a Registration Suspension no more than two (2) times in any twelve (12)-month
period. Notwithstanding the foregoing, no such delay shall exceed such number of days that Zoetis determines in good faith to be reasonably necessary. Zoetis shall (i) immediately notify the Holders upon the termination of any Registration
Suspension, (ii) amend or supplement the Prospectus, if necessary, so it does not contain any untrue statement or omission therein and (iii) furnish to the Holders such numbers of copies of the Prospectus as so amended or supplemented as
the Holders may reasonably request. 
 (e) Underwritten Offering. If the Initiating Holder so indicates at the time of
its request pursuant to Section 2.1(a), such offering of Registrable Securities shall be in the form of an Underwritten Offering and Zoetis shall include such information in the Zoetis Notice. In the event that the Initiating Holder
intends to distribute the Registrable Securities by means of an Underwritten Offering, the right of any Holder to include Registrable Securities in such Registration shall be conditioned upon such Holder’s participation in such underwriting and
the inclusion of such Holder’s Registrable Securities in the underwriting. 
 (f) Priority of Securities in an
Underwritten Offering. If the managing underwriter or underwriters of a proposed Underwritten Offering, including an Underwritten Offering from a Shelf Registration, pursuant to this Section 2.1 informs the Holders with Registrable
Securities in the proposed Underwritten Offering in writing that, in its or their opinion, the number of securities requested to be included in such Underwritten Offering exceeds the number that can be sold in such Underwritten Offering without
being likely to have an 

  
 7 

 
adverse effect on the price, timing or distribution of the securities offered or the market for the securities offered, then the securities to be included in such Underwritten Offering shall be
reduced to such number that can be sold without such adverse effect and the securities to be included in such Underwritten Offering shall be: (i) first, Registrable Securities requested by Pfizer to be included in such Underwritten Offering;
(ii) second, Registrable Securities requested by all other Holders to be included in such Underwritten Offering on a pro rata basis; and (iii) third, all other securities requested and otherwise eligible to be included in such Underwritten
Offering (including securities to be sold for the account of Zoetis) on a pro rata basis. 
 (g) Shelf Registration. At
any time after the date hereof when Zoetis is eligible to Register the applicable Registrable Securities on Form S-3 (or a successor form) and the Holder may request Demand Registrations, the requesting Holders may request Zoetis to effect a Demand
Registration as a Shelf Registration. There shall be no limitations on the number of Underwritten Offerings pursuant to a Shelf Registration; provided, however, that the Holders may not require Zoetis to effect more than four
(4) Underwritten Offerings in a twelve (12)-month period. Any Holder of Registrable Securities included on a Shelf Registration shall have the right to request that Zoetis cooperate in a shelf takedown at any time, including an Underwritten
Offering, by delivering a written request thereof to Zoetis specifying the number of shares of Registrable Securities such Holder wishes to include in the shelf takedown (“Takedown Notice”). Zoetis shall (i) within five
(5) days of the receipt of a Takedown Notice for an Underwritten Offering, give written notice of such Takedown Notice to all Holders of Registrable Securities included on such Shelf Registration (“Zoetis Takedown Notice”), and
(ii) shall take all actions reasonably requested by such Holder, including the filing of a Prospectus supplement and the other actions described in Section 2.4, in accordance with the intended method of distribution set forth in the
Takedown Notice as expeditiously as possible. If the takedown is an Underwritten Offering, Zoetis shall include in such Underwritten Offering all Registrable Securities that that the Holders request to be included within the two (2) days
following their receipt of the Zoetis Takedown Notice. If the takedown is an Underwritten Offering, the Registrable Securities requested to be included in a shelf takedown must represent (i) an aggregate offering price of Registrable Securities
that is reasonably be expected to equal at least $[            ] or (ii) all of the remaining Registrable Securities owned by the requesting Holder and its Affiliates. 

(h) SEC Form. Except as set forth in the next sentence, Zoetis shall use its reasonable best efforts to cause Demand Registrations
to be Registered on Form S-3 (or any successor form), and if Zoetis is not then eligible under the Securities Act to use Form S-3, Demand Registrations shall be Registered on Form S-1 (or any successor form). If a Demand Registration is a
Convertible or Exchange Registration, Zoetis shall effect such Registration on the appropriate Form under the Securities Act for such Registrations. Zoetis shall use its reasonable best efforts to become eligible to use Form S-3 and, after becoming
eligible to use Form S-3, shall use its reasonable best efforts to remain so eligible. All Demand Registrations shall comply with applicable requirements of the Securities Act and, together with each Prospectus included, filed or otherwise furnished
by Zoetis in connection therewith, shall not contain any untrue statement of material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. 

  
 8 

 2.2 Piggyback Registrations. 

(a) Participation. If Zoetis proposes to file a Registration Statement under the Securities Act with respect to any offering of
Zoetis Common Stock for its own account and/or for the account of any other Persons (other than a Registration (i) under Section 2.1 hereof, (ii) pursuant to a Registration Statement on Form S-8 or Form S-4 or similar form that
relates to a transaction subject to Rule 145 under the Securities Act, (iii) pursuant to any form that does not include substantially the same information as would be required to be included in a Registration Statement covering the sale of
Registrable Securities, (iv) in connection with any dividend reinvestment or similar plan, (v) for the sole purpose of offering securities to another entity or its security holders in connection with the acquisition of assets or securities
of such entity or any similar transaction or (vi) in which the only Zoetis Common Stock being Registered is Zoetis Common Stock issuable upon conversion of debt securities that are also being Registered) (a “Zoetis Public
Sale”), then, as soon as practicable (but in no event less than fifteen (15) days prior to the proposed date of filing such Registration Statement), Zoetis shall give written notice of such proposed filing to each Holder, and such
notice shall offer such Holders the opportunity to Register under such Registration Statement such number of Registrable Securities as each such Holder may request in writing (a “Piggyback Registration”). Subject to
Section 2.2(a) and Section 2.2(c), Zoetis shall include in such Registration Statement all such Registrable Securities that are requested to be included therein within fifteen (15) days after the receipt of any such
notice; provided, however, that if, at any time after giving written notice of its intention to Register any securities and prior to the effective date of the Registration Statement filed in connection with such Registration, Zoetis
shall determine for any reason not to Register or to delay Registration of such securities, Zoetis may, at its election, give written notice of such determination to each such Holder and, thereupon, (i) in the case of a determination not to
Register, shall be relieved of its obligation to Register any Registrable Securities in connection with such Registration, without prejudice, however, to the rights of any Holder to request that such Registration be effected as a Demand Registration
under Section 2.1, and (ii) in the case of a determination to delay Registration, shall be permitted to delay Registering any Registrable Securities for the same period as the delay in Registering such other shares of Zoetis Common
Stock. No Registration effected under this Section 2.2 shall relieve Zoetis of its obligation to effect any Demand Registration under Section 2.1. If the offering pursuant to a Registration Statement pursuant to this
Section 2.2 is to be an Underwritten Offering, then each Holder making a request for a Piggyback Registration pursuant to this Section 2.2(a) shall, and Zoetis shall use reasonable best efforts to coordinate arrangements with
the underwriters so that each such Holder may, participate in such Underwritten Offering. If the offering pursuant to such Registration Statement is to be on any other basis, then each Holder making a request for a Piggyback Registration pursuant to
this Section 2.2(a) shall, and Zoetis shall use reasonable best efforts to coordinate arrangements so that each such Holder may, participate in such offering on such basis. Zoetis’s filing of a Shelf Registration shall not be deemed
to be a Zoetis Public Sale; provided, however, that the proposal to file any Prospectus supplement filed pursuant to a Shelf Registration with respect to an offering of Zoetis Common Stock for its own account and/or for the account of any other
Persons will be a Zoetis Public Sale unless such offering qualifies for an exemption from Zoetis Public Sale definition in this Section 2.2(a); provided, further that if Zoetis files a Shelf Registration for its own account
and/or for the account of any other Persons, Zoetis agrees that it shall use its reasonable best efforts to include in such Registration Statement such disclosures as may be required by Rule 430B under the Securities Act in order to ensure that the
Holders may be added to such Shelf Registration at a later time through the filing of a Prospectus supplement rather than a post-effective amendment. 

  
 9 

 (b) Right to Withdraw. Each Holder shall have the right to withdraw such
Holder’s request for inclusion of its Registrable Securities in any Underwritten Offering pursuant to this Section 2.2 at any time prior to the execution of an underwriting agreement with respect thereto by giving written notice to
Zoetis of such Holder’s request to withdraw and, subject to the preceding clause, each Holder shall be permitted to withdraw all or part of such Holder’s Registrable Securities from a Piggyback Registration at any time prior to the
effective date thereof. 
 (c) Priority of Piggyback Registration. If the managing underwriter or underwriters of any
proposed Underwritten Offering of a class of Registrable Securities included in a Piggyback Registration informs Zoetis and the Holders in writing that, in its or their opinion, the number of securities of such class which such Holder and any other
Persons intend to include in such Underwritten Offering exceeds the number which can be sold in such Underwritten Offering without being likely to have an adverse effect on the price, timing or distribution of the securities offered or the market
for the securities offered, then the securities to be included in such Underwritten Offering shall be reduced to such number that can be sold without such adverse effect and the securities to be included in the Underwritten Offering shall be
(i) first, all securities of Zoetis or any other Persons for whom Zoetis is effecting the Underwritten Offering, as the case may be, proposes to sell; (ii) second, Registrable Securities requested by Pfizer to be included in such
Underwritten Offering; (iii) third, Registrable Securities requested by all other Holders to be included in such Underwritten Offering on a pro rata basis; and (iv) forth, all other securities requested and otherwise eligible to be
included in such Underwritten Offering (including securities to be sold for the account of Zoetis) on a pro rata basis. 
 2.3
Selection of Underwriter(s), Etc. In any Underwritten Offering pursuant to Section 2.1 or Section 2.2 in which a Holder is participating, Pfizer, in the event Pfizer is participating, or the Holders of a majority of
the outstanding Registrable Securities being included in the Underwritten Offering, in the event Pfizer is not participating, shall select the underwriter(s), financial printer, solicitation and/or exchange agent (if any) and Holder’s counsel
for such Underwritten Offering. 
 2.4 Registration Procedures. 

(a) In connection with the Registration and/or sale of Registrable Securities pursuant to this Agreement, through an Underwritten Offering
or otherwise, Zoetis shall use reasonable best efforts to effect or cause the Registration and the sale of such Registrable Securities in accordance with the intended methods of disposition thereof and: 

(i) prepare and file the required Registration Statement including all exhibits and financial statements required under
the Securities Act to be filed therewith, and before filing with the SEC a Registration Statement or Prospectus, or any amendments or supplements thereto, (A) furnish to the underwriters, if any, and to the Holders, copies of all documents
prepared to be filed, which documents will be subject to the review of such underwriters and such Holders and their respective counsel, and (B) not file with the SEC any Registration Statement or Prospectus or amendments or supplements thereto
to which Holders or the underwriters, if any, shall reasonably object; 

  
 10 

 (ii) except in the case of a Shelf Registration or Convertible or Exchange
Registration, prepare and file with the SEC such amendments and supplements to such Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and to comply with the
provisions of the Securities Act with respect to the disposition of all of the Shares Registered thereon until the earlier of (A) such time as all of such Shares have been disposed of in accordance with the intended methods of disposition set
forth in such Registration Statement or (B) the expiration of nine (9) months after such Registration Statement becomes effective, plus the number of days of any Registration Suspension; 

(iii) in the case of a Shelf Registration, prepare and file with the SEC such amendments and supplements to such
Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and to comply with the provisions of the Securities Act with respect to the disposition of all Shares subject
thereto for a period ending on thirty-six (36) months after the effective date of such Registration Statement; 
 (iv) in the case of a Convertible or Exchange Registration, prepare and file with the SEC such amendments and supplements to such Registration Statement and the Prospectus used in connection therewith as
may be necessary to keep such Registration Statement effective and to comply with the provisions of the Securities Act with respect to the disposition of all of the Shares subject thereto until such time as the rules, regulations and requirements of
the Securities Act and the terms of any applicable convertible securities no longer require such Shares to be Registered under the Securities Act; 
 (v) notify the participating Holders and the managing underwriter or underwriters, if any, and (if requested) confirm such advice in writing and provide copies of the relevant documents, as soon as
reasonably practicable after notice thereof is received by Zoetis (A) when the applicable Registration Statement or any amendment thereto has been filed or becomes effective, when the applicable Prospectus or any amendment or supplement to such
Prospectus has been filed, (B) of any written comments by the SEC or any request by the SEC or any other Governmental Authority for amendments or supplements to such Registration Statement or such Prospectus or for additional information,
(C) of the issuance by the SEC of any stop order suspending the effectiveness of such Registration Statement or any order preventing or suspending the use of any preliminary or final Prospectus or the initiation or threatening of any
proceedings for such purposes, (D) if, at any time, the representations and warranties of Zoetis in any applicable underwriting agreement cease to be true and correct in all material respects, and (E) of the receipt by Zoetis of any
notification with respect to the suspension of the qualification of the Registrable Securities for offering or sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; 

  
 11 

 (vi) subject to Section 2.1(d), promptly notify each selling
Holder and the managing underwriter or underwriters, if any, when Zoetis becomes aware of the occurrence of any event as a result of which the applicable Registration Statement or the Prospectus included in such Registration Statement (as then in
effect) contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements therein (in the case of such Prospectus and any preliminary Prospectus, in light of the circumstances under which they were
made) not misleading or, if for any other reason it shall be necessary during such time period to amend or supplement such Registration Statement or Prospectus in order to comply with the Securities Act and, in either case as promptly as reasonably
practicable thereafter, prepare and file with the SEC, and furnish without charge to the selling Holder and the managing underwriter or underwriters, if any, an amendment or supplement to such Registration Statement or Prospectus which will correct
such statement or omission or effect such compliance; 
 (vii) use its reasonable best efforts to prevent or
obtain the withdrawal of any stop order or other order suspending the use of any preliminary or final Prospectus; 
 (viii) promptly incorporate in a Prospectus supplement or post-effective amendment such information as the managing underwriters, if any, and the Holders may reasonably request in order to permit the
intended method of distribution of the Registrable Securities; and make all required filings of such Prospectus supplement or post-effective amendment as soon as reasonably practicable after being notified of the matters to be incorporated in such
Prospectus supplement or post-effective amendment; 
 (ix) furnish to each selling Holder and each underwriter,
if any, without charge, as many conformed copies as such Holder or underwriter may reasonably request of the applicable Registration Statement and any amendment or post-effective amendment thereto, including financial statements and schedules, all
documents incorporated therein by reference and all exhibits (including those incorporated by reference); 
 (x)
deliver to each selling Holder and each underwriter, if any, without charge, as many copies of the applicable Prospectus (including each preliminary Prospectus) and any amendment or supplement thereto as such Holder or underwriter may reasonably
request (it being understood that Zoetis consents to the use of such Prospectus or any amendment or supplement thereto by each selling Holder and the underwriters, if any, in connection with the offering and sale of the Registrable Securities
covered by such Prospectus or any amendment or supplement thereto) and such other documents as such selling Holder or underwriter may reasonably request in order to facilitate the disposition of the Registrable Securities by such Holder or
underwriter; 
 (xi) on or prior to the date on which the applicable Registration Statement is declared effective
or becomes effective, use its reasonable best efforts to register or qualify, and cooperate with each selling Holder, the managing underwriter or underwriters, if any, and their respective counsel, in connection with the registration or
qualification of such Registrable Securities for offer and sale under the securities or 

  
 12 

 
“Blue Sky” laws of each state and other jurisdiction of the United States as any selling Holder or managing underwriter or underwriters, if any, or their respective counsel reasonably
request in writing and do any and all other acts or things reasonably necessary or advisable to keep such registration or qualification in effect for so long as such Registration Statement remains in effect and so as to permit the continuance of
sales and dealings in such jurisdictions of the United States for so long as may be necessary to complete the distribution of the Registrable Securities covered by the Registration Statement; provided that Zoetis will not be required to
qualify generally to do business in any jurisdiction where it is not then so qualified or to take any action which would subject it to taxation or general service of process in any such jurisdiction where it is not then so subject; 

(xii) in connection with any sale of Registrable Securities that will result in such securities no longer being
Registrable Securities, cooperate with each selling Holder and the managing underwriter or underwriters, if any, to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be sold and not bearing any
restrictive Securities Act legends; and to register such Registrable Securities in such denominations and such names as such selling Holder or the underwriter(s), if any, may request at least two (2) Business Days prior to such sale of
Registrable Securities; provided that Zoetis may satisfy its obligations hereunder without issuing physical stock certificates through the use of the Depository Trust Company’s Direct Registration System; 

(xiii) cooperate and assist in any filings required to be made with the Financial Industry Regulatory Authority and each
securities exchange, if any, on which any of Zoetis’s securities are then listed or quoted and on each inter-dealer quotation system on which any of Zoetis’s securities are then quoted, and in the performance of any due diligence
investigation by any underwriter (including any “qualified independent underwriter”) that is required to be retained in accordance with the rules and regulations of each such exchange, and use its reasonable best efforts to cause the
Registrable Securities covered by the applicable Registration Statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the seller or sellers thereof or the underwriter or
underwriters, if any, to consummate the disposition of such Registrable Securities; 
 (xiv) not later than the
effective date of the applicable Registration Statement, provide a CUSIP number for all Registrable Securities and provide the applicable transfer agent with printed certificates for the Registrable Securities which are in a form eligible for
deposit with The Depository Trust Company; provided that Zoetis may satisfy its obligations hereunder without issuing physical stock certificates through the use of the Depository Trust Company’s Direct Registration System; 

(xv) obtain for delivery to and addressed to each selling Holder and to the underwriter or underwriters, if any, opinions
from outside counsel and the general counsel or deputy general counsel for Zoetis, in each case dated the effective date of the Registration Statement or, in the event of an Underwritten Offering, the date of the closing under the underwriting
agreement, and in each such case in customary form and content for the type of Underwritten Offering; 

  
 13 

 (xvi) in the case of an Underwritten Offering, obtain for delivery to and
addressed to Zoetis and the underwriter or underwriters and, to the extent requested, each selling Holder, a cold comfort letter from Zoetis’s independent certified public accountants in customary form and content for the type of Underwritten
Offering, dated the date of execution of the underwriting agreement and brought down to the closing under the underwriting agreement; 
 (xvii) use its reasonable best efforts to comply with all applicable rules and regulations of the SEC and make generally available to its security holders, as soon as reasonably practicable, but no later
than ninety (90) days after the end of the twelve (12)-month period beginning with the first day of Zoetis’s first quarter commencing after the effective date of the applicable Registration Statement, an earnings statement satisfying the
provisions of Section 11(a) of the Securities Act and the rules and regulations promulgated thereunder and covering the period of at least twelve (12) months, but not more than eighteen (18) months, beginning with the first month
after the effective date of the Registration Statement; 
 (xviii) provide and cause to be maintained a transfer
agent and registrar for all Registrable Securities covered by the applicable Registration Statement from and after a date not later than the effective date of such Registration Statement; 

(xix) cause all Registrable Securities covered by the applicable Registration Statement to be listed on each securities
exchange on which any of Zoetis’s securities are then listed or quoted and on each inter-dealer quotation system on which any of Zoetis’s securities are then quoted; 

(xx) provide (A) each Holder participating in the Registration, (B) the underwriters (which term, for purposes
of this Agreement, shall include a Person deemed to be an underwriter within the meaning of Section 2(11) of the Securities Act), if any, of the Registrable Securities to be Registered, (C) the sale or placement agent therefor, if any,
(D) counsel for such underwriters or agent, and (E) any attorney, accountant or other agent or representative retained by such Holder or any such underwriter, as selected by such Holder, the opportunity to participate in the preparation of
such Registration Statement, each Prospectus included therein or filed with the SEC, and each amendment or supplement thereto, and to require the insertion therein of material, furnished to Zoetis in writing, which in the reasonable judgment of such
Holder(s) and their counsel should be included; and for a reasonable period prior to the filing of such Registration Statement, make available upon reasonable notice at reasonable times and for reasonable periods for inspection by the parties
referred to in (A) through (E) above, all pertinent financial and other records, pertinent corporate documents and properties of Zoetis that are available to Zoetis, and cause all of Zoetis’s officers, directors and employees and the
independent public accountants who have certified its financial statements to make themselves available at reasonable times and for reasonable periods to discuss the business of Zoetis and to supply all information available to Zoetis reasonably
requested by any such Person in connection with such Registration Statement as shall be necessary to enable them to exercise their due diligence responsibility, subject to the foregoing; 

  
 14 

 (xxi) to cause the executive officers of Zoetis to participate in the
customary “road show” presentations that may be reasonably requested by the managing underwriter or underwriters in any Underwritten Offering and otherwise to facilitate, cooperate with, and participate in each proposed offering
contemplated herein and customary selling efforts related thereto; and 
 (xxii) take all other customary steps
reasonably necessary to effect the Registration, offering and sale of the Registrable Securities. 
 (b) As a condition
precedent to any Registration hereunder, Zoetis may require each Holder as to which any Registration is being effected to furnish to Zoetis such information regarding the distribution of such securities and such other information relating to such
Holder, its ownership of Registrable Securities and other matters as Zoetis may from time to time reasonably request in writing. Each such Holder agrees to furnish such information to Zoetis and to cooperate with Zoetis as reasonably necessary to
enable Zoetis to comply with the provisions of this Agreement. 
 (c) Pfizer agrees, and any other Holder agrees by acquisition
of such Registrable Securities, that, upon receipt of any written notice from Zoetis of the occurrence of any event of the kind described in Section 2.4(a)(vi), such Holder will forthwith discontinue disposition of Registrable Securities
pursuant to such Registration Statement until such Holder’s receipt of the copies of the supplemented or amended Prospectus contemplated by Section 2.4(a)(vi), or until such Holder is advised in writing by Zoetis that the use of the
Prospectus may be resumed, and if so directed by Zoetis, such Holder will deliver to Zoetis (at Zoetis’s expense) all copies, other than permanent file copies then in such Holder’s possession, of the Prospectus covering such Registrable
Securities current at the time of receipt of such notice. In the event Zoetis shall give any such notice, the period during which the applicable Registration Statement is required to be maintained effective shall be extended by the number of days
during the period from and including the date of the giving of such notice to and including the date when each seller of Registrable Securities covered by such Registration Statement either receives the copies of the supplemented or amended
Prospectus contemplated by Section 2.4(a)(vi) or is advised in writing by Zoetis that the use of the Prospectus may be resumed. 
 2.5 Holdback Agreements. To the extent requested in writing by the managing underwriter or underwriters of any Underwritten Offering, Zoetis agrees not to, and shall exercise commercially
reasonable efforts to obtain agreements (in the underwriters’ customary form) from its directors, executive officers and beneficial owners of five percent (5%) or more of Zoetis Common Stock not to, directly or indirectly offer, sell,
pledge, contract to sell (including any short sale), grant any option to purchase or otherwise dispose of any equity securities of Zoetis or enter into any hedging transaction relating to any equity securities of Zoetis during the ninety
(90) days beginning on pricing date of such Underwritten Offering (except as part of such Underwritten Offering or any Distribution or pursuant to registrations on Form S-8 or S-4 or any successor forms thereto) unless the managing underwriter
or underwriters otherwise agrees to a shorter period. 

  
 15 

 2.6 Underwriting Agreement in Underwritten Offerings. If requested by the managing
underwriters for any Underwritten Offering, Zoetis shall enter into an underwriting agreement with such underwriters for such offering; provided, however, that no Holder shall be required to make any representations or warranties to
Zoetis or the underwriters (other than representations and warranties regarding such Holder and such Holder’s intended method of distribution) or to undertake any indemnification obligations to Zoetis or the underwriters with respect thereto,
except as otherwise provided in Section 2.10 hereof. 
 2.7 Private Debt Exchange. If Pfizer decides to
engage in a Private Debt Exchange with one or more Participating Banks, Zoetis agrees that it will enter into a registration rights agreement with the Participating Banks at the time of such Private Debt Exchange on terms and conditions consistent
with this Agreement and reasonably satisfactory to Zoetis. In addition, Zoetis shall execute and deliver all additional documents, agreements and instruments and shall take any and all actions reasonably requested by Pfizer in connection with any
Private Debt Exchange. 
 2.8 Convertible or Exchange Registration. If any Holder of Registrable Securities offers any
options, rights, warrants or other securities issued by it or any other Person that are offered with, convertible into or exercisable or exchangeable for any Registrable Securities, the Registrable Securities underlying such options, rights,
warrants or other securities shall be eligible for Registration pursuant to Section 2.1 and Section 2.2 hereof (a “Convertible or Exchange Registration”). 

2.9 Registration Expenses Paid By Company. In the case of any Registration of Registrable Securities required pursuant to this
Agreement (including any Registration that is delayed or withdrawn) or proposed Underwritten Offering pursuant to this Agreement, Zoetis shall pay all Registration Expenses regardless of whether the Registration Statement becomes effective or the
Underwritten Offering is completed. 
 2.10 Indemnification. 

(a) Indemnification by Company. Zoetis agrees to indemnify and hold harmless, to the full extent permitted by law, each Holder,
such Holder’s Affiliates and their respective officers, directors, employees, advisors, and agents and each Person who controls (within the meaning of the Securities Act or the Exchange Act) such Persons from and against any and all losses,
claims, damages, liabilities (or actions in respect thereof, whether or not such indemnified party is a party thereto) and expenses, joint or several (including reasonable costs of investigation and legal expenses) (each, a “Loss”
and collectively “Losses”) arising out of or based upon (i) any untrue or alleged untrue statement of a material fact contained in any Registration Statement under which the sale of such Registrable Securities was Registered
under the Securities Act (including any final or preliminary Prospectus contained therein or any amendment thereof or supplement thereto or any documents incorporated by reference therein), or any such statement made in any free writing prospectus
(as defined in Rule 405 under the Securities Act) that Zoetis has filed or is required to file pursuant to Rule 433(d) of the Securities 

  
 16 

 
Act, (ii) any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of a Prospectus,
preliminary Prospectus or free writing prospectus, in light of the circumstances under which they were made) not misleading; provided, however, that Zoetis shall not be liable to any particular indemnified party in any such case to the
extent that any such Loss arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in any such Registration Statement (i) in reliance upon and in conformity with written information
furnished to Zoetis by such indemnified party expressly for use in the preparation thereof or (ii) which has been corrected in a subsequent applicable filing with the SEC but such indemnified party nonetheless failed to provide such corrected
filing to the Person asserting such Loss, in breach of the indemnified party’s obligations under applicable law. This indemnity shall be in addition to any liability Zoetis may otherwise have. Such indemnity shall remain in full force and
effect regardless of any investigation made by or on behalf of such Holder or any indemnified party and shall survive the transfer of such securities by such Holder. 
 (b) Indemnification by the Selling Holder. Each selling Holder agrees (severally and not jointly) to indemnify and hold harmless, to the full extent permitted by law, Zoetis, its directors,
officers, employees, advisors, and agents and each Person who controls Zoetis (within the meaning of the Securities Act and the Exchange Act) from and against any Losses arising out of or based upon (i) any untrue or alleged untrue statement of
a material fact contained in any Registration Statement under which the sale of such Registrable Securities was Registered under the Securities Act (including any final or preliminary Prospectus contained therein or any amendment thereof or
supplement thereto or any documents incorporated by reference therein), or any such statement made in any free writing prospectus that Zoetis has filed or is required to file pursuant to Rule 433(d) of the Securities Act, or (ii) any omission
or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of a Prospectus, preliminary Prospectus or free writing prospectus, in light of the circumstances under which
they were made) not misleading to the extent, but, in each case (i) or (ii), only to the extent, that such untrue statement or omission is contained in any information furnished in writing by such selling Holder to Zoetis specifically for
inclusion in such Registration Statement, Prospectus, preliminary Prospectus or free writing prospectus and has not been corrected in a subsequent applicable filing with the SEC provided to the Person asserting such Loss prior to or concurrently
with the sale of the Registrable Securities to such Person. In no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder under the sale of the Registrable
Securities giving rise to such indemnification obligation. This indemnity shall be in addition to any liability the selling Holder may otherwise have. Such indemnity shall remain in full force and effect regardless of any investigation made by or on
behalf of Zoetis or any indemnified party. 
 (c) Conduct of Indemnification Proceedings. Any Person entitled to
indemnification hereunder will (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that any delay or failure to so notify the indemnifying party shall relieve the
indemnifying party of its obligations hereunder to the extent that it is materially prejudiced by reason of such delay or failure) and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory
to the indemnified party; provided, however, that any Person entitled to indemnification hereunder 

  
 17 

 
shall have the right to select and employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such Person unless
(i) the indemnifying party has agreed in writing to pay such fees or expenses, (ii) the indemnifying party shall have failed to assume the defense of such claim within a reasonable time after receipt of notice of such claim from the Person
entitled to indemnification hereunder and employ counsel reasonably satisfactory to such Person, (iii) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other
indemnified parties that are different from or in addition to those available to the indemnifying party, or (iv) in the reasonable judgment of any such Person, based upon advice of its counsel, a conflict of interest may exist between such
Person and the indemnifying party with respect to such claims (in which case, if the Person notifies the indemnifying party in writing that such Person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying
party shall not have the right to assume the defense of such claim on behalf of such Person). If such defense is not assumed by the indemnifying party, the indemnifying party will not be subject to any liability for any settlement made without its
consent, but such consent may not be unreasonably withheld, conditioned or delayed. If the indemnifying party assumes the defense, the indemnifying party shall not have the right to settle such action without the consent of the indemnified party,
which consent may not be unreasonably withheld, conditioned or delayed. No indemnifying party shall consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or
plaintiff to such indemnified party of an unconditional release from all liability in respect to such claim or litigation. It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in
the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction at any one time from all such indemnified party or parties unless (x) the
employment of more than one counsel has been authorized in writing by the indemnified party or parties, (y) an indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it that are
different from or in addition to those available to the other indemnified parties or (z) a conflict or potential conflict exists or may exist (based on advice of counsel to an indemnified party) between such indemnified party and the other
indemnified parties, in each of which cases the indemnifying party shall be obligated to pay the reasonable fees and expenses of such additional counsel or counsels. 
 (d) Contribution. If for any reason the indemnification provided for in Section 2.10(a) or Section 2.10(b) is unavailable to an indemnified party or insufficient to hold it
harmless as contemplated by Section 2.10(a) or Section 2.10(b), then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such Loss in such proportion as is appropriate
to reflect the relative fault of the indemnifying party on the one hand and the indemnified party on the other hand. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to
correct or prevent such untrue statement or omission. Notwithstanding anything in this Section 2.10(d) to the contrary, no indemnifying party (other than Zoetis) shall be required pursuant to this Section 2.10(d) to
contribute any amount in excess of the amount by which the net proceeds received by such indemnifying party from the sale of Registrable Securities in the offering to which the Losses of the indemnified parties relate

  
 18 

 
(before deducting expenses, if any) exceeds the amount of any damages which such indemnifying party has otherwise been required to pay by reason of such untrue statement or omission. The parties
hereto agree that it would not be just and equitable if contribution pursuant to this Section 2.10(d) were determined by pro rata allocation or by any other method of allocation that does not take account of the equitable
considerations referred to in this Section 2.10(d). No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of
such fraudulent misrepresentation. The amount paid or payable by an indemnified party hereunder shall be deemed to include, for purposes of this Section 2.10(d), any legal or other expenses reasonably incurred by such indemnified party
in connection with investigating, preparing to defend or defending against or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or
proceeding. If indemnification is available under this Section 2.10, the indemnifying parties shall indemnify each indemnified party to the full extent provided in Section 2.10(a) and Section 2.10(b) hereof
without regard to the relative fault of said indemnifying parties or indemnified party. 
 2.11 Reporting Requirements; Rule
144. Zoetis shall use its reasonable best efforts to be and remain in compliance with the periodic filing requirements imposed under the SEC’s rules and regulations, including the Exchange Act, and any other applicable laws or rules, and
thereafter shall timely file such information, documents and reports as the SEC may require or prescribe under Section 13 or 15(d) (whichever is applicable) of the Exchange Act. If Zoetis is not required to file such reports during such period,
it will, upon the request of any Holder, make publicly available such necessary information for so long as necessary to permit sales pursuant to Rule 144 or Regulation S under the Securities Act, and it will take such further action as any Holder
may reasonably request, all to the extent required from time to time to enable such Holder to sell Registrable Securities without Registration under the Securities Act within the limitation of the exemptions provided by (a) Rule 144 or
Regulation S under the Securities Act, as such Rules may be amended from time to time, or (b) any rule or regulation hereafter adopted by the SEC. From and after the date hereof through the first anniversary of the date upon which no Holder
owns any Registrable Securities, Zoetis shall forthwith upon request furnish any Holder (i) a written statement by Zoetis as to whether it has complied with such requirements and, if not, the specifics thereof, (ii) a copy of the most
recent annual or quarterly report of Zoetis, and (iii) such other reports and documents filed by Zoetis with the SEC as such Holder may reasonably request in availing itself of an exemption for the sale of Registrable Securities without
registration under the Securities Act. 
 2.12 Other Registration Rights. Zoetis shall not grant to any Persons the right
to request Zoetis to Register any equity securities of Zoetis, or any securities convertible or exchangeable into or exercisable for such securities, whether pursuant to “demand,” “piggyback,” or other rights, unless such rights
are subject and subordinate to the rights of the Holders under this Agreement. 

  
 19 

 ARTICLE III 
 MISCELLANEOUS 
 3.1 Term. This Agreement shall terminate upon such time as
there are no Registrable Securities, except for the provisions of Section 2.9 and Section 2.10 and all of this Article III, which shall survive any such termination. 

3.2 Notices. All notices or other communications under this Agreement shall be in writing and shall be deemed to be duly given
when (a) delivered in person or (b) deposited in the United States mail or private express mail, postage prepaid, addressed as follows: 
 If to Pfizer, to: 
 Pfizer Inc. 

235 East 42nd Street 
 New York, NY 10017 
 Attention: Executive Vice President and General Counsel

 with a copy to: 
 [                            ] 

If to the Company to: 
 Zoetis Inc. 

[                      
      ] 
 with a copy to: 

[                      
      ] 
 Any party may, by notice to the other party, change the address to which such notices are to be given.

 3.3 Successors, Assigns and Transferees. This Agreement and all provisions hereof shall be binding upon and inure to
the benefit of the parties hereto and their respective successors and permitted assigns. Zoetis may assign this Agreement at any time in connection with a sale or acquisition of Zoetis, whether by merger, consolidation, sale of all or substantially
all of Zoetis’s assets, or similar transaction, without the consent of the Holders; provided that the successor or acquiring Person agrees in writing to assume all of Zoetis’s rights and obligations under this Agreement. A Holder
may assign its rights and obligations under this Agreement to any transferee that acquires at least five percent (5%) of the number of Registrable Securities beneficially owned by Pfizer immediately following the completion of the IPO and
executes an agreement to be bound hereby in the form attached hereto as Exhibit A, an executed counterpart of which shall be furnished to Zoetis. Notwithstanding the foregoing, if such transfer is subject to covenants, agreements or other
undertakings restricting transferability thereof, the Registration Rights shall not be transferred in connection with such transfer unless such transferee complies with all such covenants, agreements and other undertaking. 

  
 20 

 3.4 GOVERNING LAW; NO JURY TRIAL. 

(a) This Agreement shall be governed by and construed and interpreted in accordance with the laws of the State of New York, without regard
to the conflict of laws principles thereof that would result in the application of any law other than the laws of the State of New York. EACH OF THE PARTIES HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A
TRIAL BY JURY WITH RESPECT TO ANY COURT PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF AND PERMITTED UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH OF THE PARTIES HEREBY (A) CERTIFIES THAT
NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT HAS BEEN INDUCED TO
ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, AS APPLICABLE. 
 (b) With respect to any Action
relating to or arising out of this Agreement, each party to this Agreement irrevocably (a) consents and submits to the exclusive jurisdiction of the courts of the State of New York and any court of the United States located in the Borough of
Manhattan in New York City; (b) waives any objection which such party may have at any time to the laying of venue of any Action brought in any such court, waives any claim that such Action has been brought in an inconvenient forum and further
waives the right to object, with respect to such Action, that such court does not have jurisdiction over such party; and (c) consents to the service of process at the address set forth for notices in Section 3.2 herein;
provided, however, that such manner of service of process shall not preclude the service of process in any other manner permitted under applicable law. 
 3.5 Specific Performance. In the event of any actual or threatened default in, or breach of, any of the terms, conditions and provisions of this Agreement, the party or parties who are or are to be
thereby aggrieved shall have the right to seek specific performance and injunctive or other equitable relief of its rights under this Agreement, in addition to any and all other rights and remedies at law or in equity, and all such rights and
remedies shall be cumulative. 
 3.6 Headings. The article, section and paragraph headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 
 3.7
Severability. If any provision of this Agreement or the application thereof to any Person or circumstance is determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions hereof or the
application of such provision to Persons or circumstances or in jurisdictions other than those as to which it has been held invalid or unenforceable, shall remain in full force and effect and shall in no way be affected, impaired or

  
 21 

 
invalidated thereby, so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner adverse to any party. Upon such determination, the parties
shall negotiate in good faith in an effort to agree upon such a suitable and equitable provision to effect the original intent of the parties. 
 3.8 Amendment; Waiver. 
 (a) This Agreement may not be amended or modified
and waivers and consents to departures from the provisions hereof may not be given, except by an instrument or instruments in writing making specific reference to this Agreement and signed by Zoetis and the Holders of a majority of the Registrable
Securities; provided that if Pfizer or any of its Affiliates owns Registrable Securities, no amendment to or waiver of any provision in this Agreement will be effected without the written consent of Pfizer if such amendment or waiver
adversely affects the rights of Pfizer or such Affiliates of Pfizer. 
 (b) Waiver by any party of any default by the other
party of any provision of this Agreement shall not be deemed a waiver by the waiving party of any subsequent or other default, nor shall it prejudice the rights of the other party. 

3.9 Further Assurances. Each of the parties hereto shall execute and deliver all additional documents, agreements and instruments
and shall do any and all acts and things reasonably requested by the other party hereto in connection with the performance of its obligations undertaken in this Agreement. 
 3.10 Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when one or more counterparts
have been signed by each of the parties and delivered to the other party. Execution of this Agreement or any other documents pursuant to this Agreement by facsimile or other electronic copy of a signature shall be deemed to be, and shall have the
same effect as, executed by an original signature. 
 [The remainder of page intentionally left blank. Signature page
follows.] 

  
 22 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of
the date first written above. 
  

					
	PFIZER INC.
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	
	
	ZOETIS INC.
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

 EXHIBIT A 
 THIS INSTRUMENT forms part of the Registration Rights Agreement (the “Agreement”), dated as of __________, _____, by and among Zoetis Inc., a Delaware corporation, and Pfizer Inc., a
Delaware corporation (“Pfizer”). The undersigned hereby acknowledges having received a copy of the Agreement and having read the Agreement in its entirety, and for good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, and intending to be legally bound, hereby agrees that the terms and conditions of the Agreement binding upon and inuring to the benefit of Pfizer shall be binding upon and inure to the benefit of the undersigned and its
successors and permitted assigns as if it were an original party to the Agreement. 
 IN WITNESS WHEREOF, the undersigned has
executed this instrument on this        day of                    . 

 

	
	  
	(Signature of Transferee)
	
	  
	Print Name

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]